Dompé Farmaceutici S.p.A.                      Clinical Study Report REPAVID-19 Phase 3                        Appendix 16.1.1 
 
16.1.1 Protocol and protocol amendments 
Protocol REP0220 –  Final Version 3.0, 09 April 2021  
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 2 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
TABLE OF CONTENTS  
 
1. SIGNATURES  ........................................................................................................ 5 
2. CONTACT INFORMATION  ................................................................................ 8 
3. LIST OF ABBREVIATIONS  ................................................................................ 9 
4. PROTOCOL SYNOPSIS  ..................................................................................... 11 
1. INTRODUCTION  ................................................................................................ 21 
1.1 Background ............................................................................................................. 21 
1.2 Mechanism of action of Reparixin  .......................................................................... 21 
1.3 Toxicology data  ...................................................................................................... 24 
1.4 Pharmacokinetics and product metabolism  ............................................................ 24 
1.5 Clinical development  .............................................................................................. 25 
1.7 Phase 2 study  .......................................................................................................... 28 
1.8 Phase 3 stud y .......................................................................................................... 28 
2. STUDY OBJECTIVES AND ENDPOINTS  ....................................................... 28 
2.1 Study objectives ...................................................................................................... 28 
2.2 Primary Endpoint .................................................................................................... 28 
2.3 Key Secondary Endpoints ....................................................................................... 28 
2.4 Additional Secondary Endpoints ............................................................................ 29 
2.5  ............................................................................................ 29 
2.6 Safety Endpoints ..................................................................................................... 30 
3. STUDY DES IGN AND METHODOLOGY  ....................................................... 30 
3.1 Study design ............................................................................................................ 30 
3.2 Study population ..................................................................................................... 31 
3.3 Study du ration  ......................................................................................................... 31 
3.4 Description of the study  .......................................................................................... 31 
4. STUDY POPULATION ....................................................................................... 32 
4.1 Number of patients .................................................................................................. 32 
4.2 Inclusion/exclusion criteria ..................................................................................... 33  
4.2.1  Inclusion Criteria: ................................................................................................... 
33 
4.2.2  Exclusion Criteria: .................................................................................................. 33 
5. TREATMENTS  .................................................................................................... 34 
CCI

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 3 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
5.1 Investigational products .......................................................................................... 34 
5.1.1  Dose regimen and administration ........................................................................... 34 
5.1.2  Randomization ........................................................................................................ 35 
5.1.3  Unblinding .............................................................................................................. 35 
5.1.4  Compliance to Treatment  ........................................................................................ 36 
5.2 Other treatments  ...................................................................................................... 36 
5.2.1  Additional therapy .................................................................................................. 36 
5.2.3  Concomitant and not allowed medications ............................................................. 37 
5.3  Preparation, Handling, Storage and Accountability of the study drugs .................. 38 
5.3.1  Reparixin ................................................................................................................. 38 
5.3.2  Placebo  .................................................................................................................... 38 
5.3.3  Management, Packaging and Labelling of Investigational Products ...................... 38 
6. DISCONTINUATIONS  ........................................................................................................ 39 
7. ASSESSMENTS AND PROCEDURES  .............................................................................. 40 
7.1 Procedures ............................................................................................................... 40 
7.2  Screening and Baseline assessments  ....................................................................... 41 
7.3 On-treatment assessments  ....................................................................................... 42 
7.4 Follow-up ................................................................................................................ 42 
7.5  ......................................................................... 43 
8. EVALUATION OF ADVERSE EVENTS AND SAFETY INFORMATION  ................. 45 
8.1 Definitions  .............................................................................................................. 45 
8.2 Monitoring for adverse events ................................................................................ 47 
8.3  Recording of adverse events ................................................................................... 47 
8.4 Relationship and severity of AEs to the Investigational product ............................ 47 
8.5 Follow-up of patients with adverse events ...... Errore. Il segnalibro non è definito.  
8.6 Serious adverse events reporting  ............................................................................ 49 
8.7  Exposure to investigational product during pregnancy........................................... 50 8.8 Adverse events causing treatment discontinuation  ................................................. 51 
8.9 Overdose ................................................................................................................. 51  
9. DATA MONITORING  COMMI T
TEE  ............................................................................. 51 
10. STATISTICAL CONSIDERATIONS  ............................................................................... 52 
10.1  Sample size  ............................................................................................................. 52 
10.2  Overview of planned statistical analyses  ................................................................ 52 
10.3  Analysis Population ................................................................................................ 52 
10.4  Intermediate analyses  .............................................................................................. 53 
10.4.1  Interim analysis  ....................................................................................................... 53 
10.4.2  Key first efficacy analysis  ....................................................................................... 53 
10.5  Statistical Methodology  .......................................................................................... 54 
CCI

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 4 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
10.5.1  General Considerations ........................................................................................... 54 
10.5.2  Analysis of efficacy variables  ................................................................................. 54 
10.5.2.1  Primary analysis  ...................................................................................................... 54 
10.5.2.2  Sensitivity analyses  ................................................................................................. 55 
10.5.2.3  Secondary Analyses ................................................................................................ 55 
10.5.3  Safety Analysis ....................................................................................................... 56 
10.5.4   ........................................................................... 56 
10.5.5  Intermediate analyses for DMC  .............................................................................. 56 
10.5.6  Specification of subgroups for analysis  .................................................................. 56 
10.5.7  Missing data  ............................................................................................................ 57 
11 STUDY ORGANIZATION .................................................................................. 58 
11.1  Study documentation and record keeping  ............................................................... 58 
11.2  Ethical considerations, quality assurance and monitoring ...................................... 58 
11.3  Informed consent .................................................................................................... 58 
11.4  Data  collection  ........................................................................................................ 59 
11.5  Confidentiality and data protection ......................................................................... 59 
11.6  Unique subject identifier  ......................................................................................... 59 
11.7  Database management  ............................................................................................ 60 
11.8  Coding dictionaries ................................................................................................. 60 
11.9  Publication policy  ................................................................................................... 60 
11.10  Admi nistrative aspects  ............................................................................................ 60 
12 REFERENCES ...................................................................................................... 61 
13 APPENDICES  ....................................................................................................... 66 
Appendix 1. Investigator’s Brochure (IB)  ................................................................................... 66 
Appendix 2. Investigational Drug Labels .................................................................................... 66 
Appendix 3. Severe Adverse Event (SAE) reporting form and completion guideline ................ 66 
Appendix 4. Pregnancy reporting form and completion guideline ............................................. 66 Appendix 5. Informed c onsent form  ........................................................................................... 66 
 
 
 
 
   
 
    
 
 
CCI

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 7 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
 INVESTIGATOR’S SIGNATURE PAGE  
 
A phase 3, double -blind, randomized, placebo -controlled , multicenter study on the efficacy and safety of Reparixin 
in the treatment of hospitalized patients with severe COVID- 19 pneumonia  
Version 3.0 09 April 2021  
 
Investigator’s Statement  
 
I have read this study protocol and agree to conduct the study as outlined in the protocol, and in accordance with 
the Declaration of Helsinki, ICH-GCP  E6 (R2) and any local regulations, being responsible for personally 
supervise the study conduct and ensure study staff complies with protocol requirement.  
 
 
Name of Principal Investigator (block letters): ____________________________________________ 
 
 
 
Signature:  _______________________________  Date:   _________________________  
 
 
 
 
     
 
    
 
     
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 9 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
3. LIST OF ABBREVIATIONS  
 
AE Adverse Event  
ALI Acute Lung Injury  
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase  
ARDS  Acute Respiratory Distress Syndrome  
AST  Aspartate Aminotransferase  
AUC  Area Under the Curve  
BAL  Broncho -Alveolar Lavage  
CDE  Cat Dander Extract  
CIF cumulative incidence function  
Cmax  Maximum concentration  
CRO  Contract Research Organization  
CRP  C-Reactive Protein  
COVID  Corona Virus Disease  
Css Concentration, steady state  
CT Computerized Tomography  
CXC  Cisteina X Cisteina (chemochine)  
CYP  Cytochrome P450   
DB Data Base  
DBP  Diastolic Blood Pressure  
DMC  Data Monitoring Committee  
EC Ethic s Committee   
  
ECMO  Extracorporeal Membrane Oxygenation  
eCRF  electronic Case Record Form  
eGFR  Estimated Glomerular Filtration Rate  
EMA  European Medicines Agency  
EoS End of Study  
EoT End of Treatment  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FiO 2 Fraction of inspiration O 2  
GCP  Good Clinical Practice  
GGT  Gamma Glutamyl Transferase  
Hb Hemoglobin  
Hct Hematocrit  
HR Heart Rate  
ICF Informed Consent Form  
ICU Intensive Care Unit  
IEC Independent Ethics Committee  
IL Interleukin  
IMP Investigational Medicinal Product  
IMPD  Investigational Medicinal Product Dossier  
INR International Normalized Ratio  
IRB Institutional Review Board  
CCI
    CONFORMED COPY TO THE ORIGINAL   
 
   Page 10 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
IRS Interactive Response System  
ITT Intentio to Treat  
  
KM Kaplan -Meier  
LD50  Lethal  Dose 50%  
LDH  Lactate dehydrogenase  
LLN  Lower Limit of Normal  
MDRD  Modification of Diet in Renal Disease  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
ml Milliliters  
NCI-CTCAE  National Cancer Institute, Common Terminology Criteria for Adverse Events  
OATP  Organic -Anion -Transporting Polypeptides  
PaO 2 Partial pressure of oxygen  
PCR  Polymerase Chain Reaction  
P/F PaO 2 / FiO 2 
Pk Pharmacokinetic  
  
PMN  Polymorphonuclear  cell 
PP Per Protocol  
PT Preferred Term  
RR Respiratory Rate  
SAE  Serious Adverse Event  
SAF Safety Analysis Set  
SAP Statistical Analysis Plan  
SBP Systolic Blood Pressure  
SC Steering Committee  
SCM  Single Challenge Model 
SmPC  Summary of Product Characteristics  
SpO 2 peripheral capillary oxygen saturation  
SOC  System Organ Class  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TID Three times daily  
ULN  Upper Limit of Normal  
VAS  Visual Analogue Scale  
XDP  Cross -Linked Fibrin Degradation Product  
yrs years  
WBC  White Blood Cell  
WHO  World Health Organization  
WHO -OS WHO Ordinal Scale  
 
 
   

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 12 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
o Proportion of patients alive and free of respiratory failure at Day 28, i.e. with no need of invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) or admission to Intensive  Care Unit (ICU) linked to worsening of respiratory parameters 
compared to baseline.  
 
Key Secondary Endpoints:  
o Proportion of patients alive and free of respiratory failure  (as described for the primary 
endpoint ) at Day 60 .  
o Mortality rates up to  Day 28, 
o Incidence of ICU admission until Day 28,   
o Time to recovery (category 1 - 2 - 3 of the 7 -point WHO Ordinal Scale of clinical 
improvement (WHO -OS) until Day 28.  
 
 
Additional Secondary Endpoints:  
o Proportion of subjects alive and free of respirator y failure  (as described for the primary 
endpoint) at fixed time -points: days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) - 60 (±2) after 
randomization ( randomization = day 1 ),  
o Mean changes in clinical severity score based on the 7- point WHO -OS as measured at days  
3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2)  - 60 (±2) - 90 (±2) after randomization , 
o Time to clinical improvement 1 (decline of 1 category in the 7- point WHO -OS) up to Day 
28,  
o Time to clinical improvement 2 (decline of 2 categories in the 7 -point WHO -OS) up to Day 
28, 
o Time to discharge from hospital (up to day 28) , 
o Clinical status at days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) - 60 (±2)  - 90 (±2)  either in 
hospital or at home (7- point WHO -OS). When patient is at home, his/her clinical status can  
be assessed by phone , 
o Dyspnea severity (Liker t scale and VAS scale)  at days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 
(±2) or until discharge , 
o Duration of supplemental oxygen treatment  (days)  up to Day 28,  
o Incidence of invasive mechanical ventilation use, or ECMO up to Day 60, 
o Duration of invasive mechanical ventilation , or ECMO (days) up to Day 60, 
o Duration of non -invasive mechanical ventilation  (days)  up to Day 28 , 
o Duration of ICU admission (days)  up to Day60,  
o Duration of hospitalization since randomization (days)  up to Day 28, 
o Partial pressure of oxygen  (PaO 2): change from baseline to the firstly available daily value 
at days  3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) or until discharge , 
o Pulse oximetry by measurement of peripheral arterial oxygen saturation  (SpO 2): change 
from baseline to the firstly available daily value at days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 
(±2) or until discharge , 
o P/F ratio [p artial arterio lar oxygen pressure (PaO2) to fraction of  inspiration O 2 (FiO 2) ratio ] 
from baseline  to days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) or until discharge , 
o Hs-CRP : change from baseline  to days 3 - 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) or until 
discharge (alternatively, CRP) , 
o Mortality rates up to Day 60 and Day 90,  
o Freedom from (time to) death or respiratory failure ( as described for the primary end -point ). 
 
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 14 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
Inclusion Criteria: 
1. Age 18 to 90, male and f emale subject of any race  
2. Reverse transcriptase Polymerase Chain Reaction ( rt-PCR) -confirmed COVID -19 infection based on a 
nasal / oropharyngeal swab within 10 days before randomization 
3. At least one of the following : 1) Respiratory distress  with tachypnea ( RR ≥ 24 breaths/min  without 
oxygen) ; 2) Partial arterial oxygen pressure (PaO 2) / Fraction of inspiration O 2 (FiO 2) >100 and <300 
mmHg (1mmHg = 0.133kPa), 3) SpO 2 ≤ 94% while breathing ambient air .  
Calculation th rough validated Sat/FiO2 scales is  allowed . 
P/F value of reference if the last available before the signature of consent  
4. Need of supplemental oxygen  (i.e. new use of supplemental oxygen, or increased oxygen requirement if 
on chronic oxygen) requir ing low - or high- flow oxygen or  non-invasive  mechanical ventilation  (7-point 
WHO -OS category 4 or 5)  
5. Radiological c hest imaging (X -rays, CT scan) confirms lung involvement and inflammation (presence of 
ground- glass opacities, and/or inter/intra lobular septal thickening, and/or consolidations in a patchy 
distribution ).  
6. Inflammatory status as documented by at least one of the following: Lactate dehydrogenase (LDH) > 
normal range, C -reactive protein (CRP) ≥ 100 mg/L or IL -6 ≥ 40 pg/mL, serum ferritin ≥ 900 ng/mL, 
XDP > 20 mcg/mL.  
7. Females of child -bearing potential and with an active sexual life must not wish to get pregnant within 30 
days after the end of the study and must be using at least one of the following reliable methods of 
contraception:  
i) Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 
2 months before the screening visit until 30 days after final visit  
ii) A non- hormonal intrauterine device [IUD] or female condom with spermicide or contrace ptive 
sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 
months before the screening visit until 30 days after final visit  
iii) A male sexual partner who agrees to use a male condom with spermicide  
iv) A sterile sex ual partner  
Female participants of non -child -bearing potential or in post -menopausal status for at least 1 year will be 
admitted. For all female subjects, with child -bearing potential, pregnancy test result must be negative 
before first drug intake.  
 
Exclusion Criteria: 
1. Cannot obtain informed consent.  
2. hepatic dysfunction with Child Pugh score B or C, or ALT or AST  > 5 times the upper limit;  
3. renal dysfunction with estimated glomerular filtration rate  (MDRD)  <  5 0  m L /min/1.73 m2 or patient 
receiv ing continuous renal replacement therapy, hemodialysis, or peritoneal dialysis . 
4. Bacterial sepsis  (besides COVID -19 sepsis) 
5. Positive test for influenza virus, if tested during the current illness ( note: influenza testing is not required 
by protocol)  
6. Known congenital or acquired immune deficiency ,  
7. Patients with hypersensitivity to ibuprofen or to more than one non- steroidal anti- inflammatory drug or 
to more than one medication belonging to the class of sulfonamides (e.g. sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib  
Hypersensitivity to sulphanilamide antibiotics, e.g. sulfamethoxazole, does not qualify for exclusion).  
Know allergy to any medication (either investigational or non- investigational) which is planned at study 
entry for use during the study.  
8. Patients receiving other not allowed medications ( see Section: Not allowed medications ) 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 15 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
9. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment.  
10. Evidence of COVID -19 disease progression during previous ly initiated  treatm ent with remdesivir (alone 
on in any combination with other antiviral treatments), protease inhibitors (e.g. ritonavir, lopinavir, darunavir – atazanavir) , tyrosine kinase i nhibitors (e.g. baricitinib, imatinib, gefitinib) , convalescent 
plasma or intravenous immunoglobulin for COVID -19, or investigational treatments  
11. More than three infusions of remdesivir, including the loading dose , prior to randomization  
12. Subject participating in other interventional clinical trials. Subject having received investigational therapy in the previous 3 days, or at least 5 half -lives.  
13. At the time of enrollment, patients not in a clinical condition compatible with the oral administration of the study drug.  
14. P/F < 100 mmHg  
15. Pregnancy:  
a) positive or missing pregnancy test before first drug intake or day 1;  
b) pregnant or lactating women;  Women of childbearing potential and fertile men who do not agree to use at least one primary form of                       contraception for the duration of the study  
  Study treatments:  Patients who satisfy the predefined inclusion and exclusion criteria for this trial will be randomized 2:1 to one of 
the following groups  for in -hospital  treatment: 
 
Group 1: Reparixin oral tablets 1200 mg TID (2 tablets, 600 mg each, TID)  for up to 21 days or until decision of 
discharge from the hospital, on top of standard supportive care .   
 Group 2 (control):  
placebo , 2 tablets TID  (identical to R eparixin tablets) for up to 21 days or until decision of 
discharge from the hospital, on top of standard supportive care .  
 
Randomization will be performed through an Interactive Response System (IRS ). Each Patient ’s Kit number will 
be randomly associated with a treatment group. The randomization list will be provided to the facility responsible 
for IMP packaging/labelling for the purpose of IMP preparation. Each randomized patient will be allocated with randomization  number according to the stratified randomization list. Dropouts after randomization will not be 
replaced .  
Randomization will be stratified by site , gender and age class (<65 yrs vs ≥ 65 yrs) to ensure balanced assignment 
across treatment groups. The stratified permuted block randomization list will be generated with a computer procedure by an independent statistician not involved in the conduct of the study.  
  Unblinding :   
For each randomized subject, individual code breaks will be accessible in the event of a medical emergency requiring knowledge of the treatment assigned to the subject. Only the responsible investigator, or authorized delegates, can break the code via the IRT.  
Any breaking of the treatment code by the investigational staff must be reported immediately to the Sponsor and 
must include an explanation for breaking the code. The sponsor should be contacted to discuss the case, if possible, 
prior to unblinding.   
A general rule is that breaking the code is only allowed if the knowledge of the a ctual treatment is necessary for 
an appropriate decision on actions / treatments for the safety of the patient.  
The DMC will have access to group -unblinded and/or fully unblinded DMC reports.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 16 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
The sponsor ’s personnel from the Pharmacovigilance Department  of Dompé may break the treatment code for 
subjects who experience a Suspected Unexpected Serious  Adverse Reaction (SUSAR), in order to determine if the 
individual case requires expedited regulatory reporting . 
  Additional thera py : 
Any additional  therapy must be considered as local standard of care treatment, and it must be able to be 
administered  to all patients enrolled in the study. I nvestigators are allowed to provide any medications having 
received final or conditional app roval for the treatment of the COVID -19 infection, or used off -label at the 
Investigator’s discretion  and justified by scientific evidence of effectiveness against the COVID- 19 infection  
without to stop study treatment.  
 
 
 Not allowed medications:   
Not allowed medications  (either at screening, or introduced during the trial) include concomitant drugs for which 
a significant drug -drug interaction leading to metabolic alterations is suspected based on the respective metabolic 
pathways.  
Reparixin is cataly sed by CYP2C9 and to a lesser extent by CYP2C19.  Reparixin has some potential in -vitro for 
a non- competitive inhibition of the human hepatic enzyme CYP3A4.    
However, at the present time, clinically significant untoward pharmacological interactions are not  known for 
reparixin .  
For remdesivir (recently receiving conditional approval for the treatment of COVID- 19; June 2020) no clinical 
interaction studies have been performed and t he overall potential of this drug for interactions is currently unknown. 
Howev er, reparixin is not a substrate of the microsomal enzymes of which remdesivir is an in-vitro  inhibitor 
(
CYP3A4, OATP1B1 , OATP1B3 ) or inducer ( CYP1A2 , CYP3A) .  
Patients should remain under close observation during the days of remdesivir administration if given concomitantly 
with reparixin . 
  Study duration:   
The treatment duration will be up to a maximum of 21 days , with a follow -up period lasting up to 90 days si nce 
baseline.  
The treatment will be interrupted upon the Investigator’s clinical judgment  of the patient’s improvement, even if 
the patient is still h ospitalized  but no longer requiring suppl emental  oxygen or  significant medical care. 
The treatment is not foreseen to be continued at home .  
For subjects discharged home before the completion of the 21- day treatment period, follow -up visits (preferably 
in person at the Center, or via a telephone call) will be held at days 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) - 60 (±2) 
and/or 90 (±2) depending on the discharge time point .   
  End of study (EOS) definition: EOS  is defined as the last day the last patient completes the last study assessment 
(including the follow -up assessments), or withdraws the consent to participate in the study including refusal to 
undergo follow -up, or is deceased or otherwise lost to follow -up.  
 End of treatment (EOT) definition: EO T is defined as the last treatment day in a randomized patient. EOT occurs 
upon completion of the scheduled treatment period (up to 21 days)  for clinical judgment of improvement , or at the 
time of discharge from hospital, or at any time the treatment is interrupted early for any reason (e.g. for adverse events, ineffectiveness, withdrawal of consent for treatment). Patients randomized but with no actual treatment initiated, will have their EOT on the date of random ization.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 17 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
  Stopping criteria for individual subjects :  
Subjects should be prematurely discontinued from study treatment for any of the following reasons:  
• subject no longer consents to participate in the treatment phase of the study , yet  consenting for the 
continuation of the collection of information in the follow -up phase of the study (specific consent to be 
signed). Patient may eventually decide to withdraw the consent for the study continuation  including the 
collection of information in the follow -up phase,  
• physician decision that it is in the best interest of the subject to be discontinued from study treatment , 
• physician decision because of poor efficacy or poor tolerability of the investigational treatment  
• the treatment will be inter rupted in case of significant worsening of the renal function with eGFR 
(MDRD) falling to below 30 ml/min/1.75m
2 or an increase of serum creatinine by more than 50% since 
randomization  
• severe protocol deviations  
All study subjects, including ‘treatment’ d rop-outs for any reason, will have to be followed up until the End of 
Study, unless the patient withdraws his/her consent to the study continuation including the follow -up.  
 
 
Stopping criteria  for the clinical trial:   
The Sponsor may terminate this study prematurely, either in its entirety or at any study site,  for reasonable cause 
provided that written notice is submitted in advance of the intended termination. Advance notice is not required if 
the study is stopped due to safety concerns.  
The recommendations of the Data Monitoring Committee  will be taken into consideration in this regard.   
If the Sponsor terminates the study for safety reasons, the Sponsor will immediately notify the investigator and 
subsequently provide written instructions for study termination .  
  Data Monitoring Committee (DMC):  An independent Data Monitoring Committee (DMC)  will be appointed 
with the responsibil ity of safeguarding the interests of trial participants, assessing the safety and efficacy of the 
interventions during the trial, and monitoring the overall conduct of the clinical trial.  These tasks will be 
accomplished  on an ongoing basis throughout the trial . The DMC will provide recommendations about stopping 
or continuing the trial. In order t o contribute to enhancing the integrity of the trial, the DMC may also formulate 
recommendations relating to the selection/recruitment/retention of participants, their management, improving adherence to protocol - specified regimens and retention of participant s, and the procedures for data management 
and quality control .  
The DMC will be advisory to the clinical trial leadership group  (the Scientific Committee  of the study) . The 
Scientific Committee will be comprised of the sponsor’s study team and lead study i nvestigators, who jointly will 
have responsibility for the design, conduct and analysis of the clinical trial. The Scientific Committee will be responsible for promptly reviewing the DMC recommendations, to decide whether to continue or terminate the trial, and to determine whether amendments to the protocol or changes in the study conduct are required.  
 Statistical plan:   
The sample size of the study is calculated based on results from the REPAVID -19 study (phase II, open label 
study) with Reparixin.  
Each patient will be randomly allocated to Reparixin or Control according to a randomization ratio of 2:1 and followed for t he entire treatment and follow -up duration for collecting the efficacy endpoints.  
Considering a randomization ratio 2:1 (Reparixin:placebo) and a one -sided alpha of 0.025, a total of 264 evaluable 
patients will allow to achieve a n overall  power of 90% to detect a group difference  ≥20% in proportion of patients 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 18 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
alive and free of respiratory failure at Day 28 in favor of reparixin, assuming that the proportion of patients  alive 
and free of respiratory failure  in the placebo group will be approximately 60%.  Assuming that 15% of subjects 
will not be evaluable for primary analysis, a total of approximately 312 subjects is expected to be enrolled.  
An interim analysis for efficacy and futility is planned when half of the planned patients has reached the primary endpoints. O’Brien- Fleming spending functions will be used to control the type I and II errors. No additional 
correction for multiplicity is required.  The DMC will be involved in the evaluation of the interim analysis results 
and in the consequent decision on the continuation of the study.  
Summary statistics have been defined for quantitative variables (number of observations, mean, standard deviation, median, minimum and maximum) and qualitative variables (number and percentage per category). If appropriate,  
confidence intervals around the mean or the proportions will be presented. For time -to-event variables, cumulative 
freedom from event will be evaluated using Kaplan- Meier (KM) method and comparison of curves among arms 
will be performed with the log -rank test. KM graphs will be presented along with the number of subject -at-risk at 
exact time points.  
Primary endpoint will be analyzed by means of logistic regression adjusting by pre -defined baseline factors .  Since 
patients who discontinue the IMP will not be withdrawn from the study but will be asked to complete safety and efficacy assessments, missing data will be addressed by modeling patients with missing data after retrieved drop -
outs, assuming that missing data would have been like retrieved drop- outs i f they were assessed. 
Results of primary analysis will be assessed in sensitivity analyses to assess the robustness of results on primary endpoint versus adherence to protocol and presence of missing data . 
If the primary analysis of primary endpoint leads to rejection of the null hypotheses, key secondary endpoints will be tested in a conditional sequential manner to show superiority of reparixin versus placebo according to the pre -
defined ranking sequence. Independently of the results on primary endpoints,  all secondary endpoints will be 
analyzed at each available time points by means of summary statistics and by appropriate parametric tests 
depending on the nature of the variable and its distribution. All analyses will be descriptively in nature. Data 
transformation might be used in order to satisfy the assumption of normality requested by parametric statistical 
tests. In case such assumptions are not met, non- parametric counterpart tests will be used. Change from baseline 
value (for continuous variables) a nd shift tables versus baseline (for categorical variables) will also be summarized 
for all post- baseline visits.  
AEs will be presented in terms of the number of AEs and incidence. Other safety parameters will be summarized by treatment at each available v isit by means of descriptive statistics.  
The Safety and the Full Analysis Set population will consist of all patients who will be randomized and received at least one dose of the investigational product. Safety population will be analyzed according to the  actual treatment 
received; Full Analysis Set population will be analyzed according to ITT principle, i.e. by treatment allocation. The Per Protocol (PP) population will consist of all patients in the FAS population who do not have Major Protocol 
Deviation s. Primary and secondary efficacy analyses will be conducted on the FAS population while SAF and PP 
populations will be used for safety and sensitivity analyses, respectively.  
The Study Statistical Analysis Plan (SAP) with more technical and detailed elabo ration of the principal features 
of statistical analyses will be finalized before interim analysis. Any deviation from the original statistical plan will 
be described in the Clinical Study Report.   
 
SCHEDULE OF ASSESSMENTS  
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 21 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
      
1. INTRODUCTION 
1.1 Background  
IN DECEMBER  2019,  A NEW IDENTIFIED CORONAVIRUS (SARS -COV-2) OUTBREAK IN WUHAN CAUS ED PUBLIC HEALTH 
CRISIS IN CHINA AND SPREAD WORLDWIDE . On February 11, 2020, the World Health Organization officially named 
the disease caused by the new coronavirus : "COVID- 19". The symptoms of human infection with SARS -CoV -2 
are generally fever, fatigue, dry cough and dyspnea. Noteworthy, a considerable percentage of COVID -19 cases 
have rapidly progressed to a severe and critical condition with  acute lung injury (ALI) , acute respirator y distress 
syndrome (ARDS)  and pulmonary edema  as the most common complications, resulting in a large number of 
pneumonia hospitalized patients requiring supplemental oxygen, mechanical ventilation, or even ECMO.   
 L
UNG EDEMA , ENDOTHELIAL AND EPITHELIAL INJURY ARE ACCOMPANIED BY AN INFLUX OF NEUTROPHILS INTO THE 
INTERSTITIUM AND BRONCHEOALVEOLAR SPACE . Activation and transmigration of neutrophils are considered to 
play a key role in the progression of ALI and ARDS ( 1). Proof for the importance of neutrophils in ALI comes 
from clinical data and animal models. In patients with ARDS, the concentration of neutrophils in the bronchoalveolar lavage (BAL) fluid correlates with severity of ARDS and outcome ( 2; 3), whereas the severity of 
lung injury has been reduced by neutrophil depletion in mice. Furthermore, after blocking interleukin -8 (IL -8), a 
major chemoattractant for neutrophils, rabbits have been protected from acid aspiration- induced lung injury. A 
multitude of experimental and clinical data point at the causative role of neutrophils in lung injury ( 1-57). Although 
neutrophil activation is vital for the host defense, overzealous activation leads to tissue damage by release of cytotoxic and immune cell –activ ating agents such as proteinases, cationic polypeptides, cytokines, and reactive 
oxygen species.   
1.2 Mechanism of action of Reparixin  
 
NUMEROUS STUDIES HAVE CONFIRMED A KEY ROLE OF CXCR1/CXCR2  RECEPTOR AS POTENTIAL THERAPEUTIC 
TARGET IN ACUTE LUNG INJURY (ALI)  AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS).  Neutrophil 
infiltration of the lung is controlled by a complex network of chemokines that are released by a variety of cell types . Alveolar macrophages are a major source of chemokines in the alveolar space and produce IL -8, growth-
regulated oncogene (GRO) -related peptides and CXCL5 (also known as epithelial neutrophil -activating protein 
[ENA] -78) (58; 59) (60; 61). High concentrations of IL -8 in BAL fluid from ARDS patients are associated with 
increased neutrophil influx into the airspace ( 62; 63). Recent studies have revealed that IL -8 in BAL fluid is bound 
to IL -8 autoantibodies (anti -IL-8:IL-8 complexes) ( 64; 65) and BAL fluid concentrations of these complexes 
correlate with development and outcome of ALI ( 66; 67). In particular, this complex exhibits chemotactic and 
proinflammatory activity ( 68). Moreover, intratracheal application of IL -8 induces lung injury which can be 
attenuated by  inhibition in different models of ALI ( 69). In rodents, the most relevant chemokines for neutrophil 
recruitment into the lung are keratinocyte -derived chemokine (KC, also named CXCL1) or cytokine -induced 
neutrophil chemoattractant (CINC; the rat homolo g to KC) and macrophage inflammatory protein- 2 (MIP -2, also 
named CXCL2). Similar to IL -8, CXCL1, CXCL2, lipopolysaccharide -induced CXC chemokine (LIX, also named 
CXCL5) and lungkine (CXCL15) bind to CXCR2. Inhibition or knockout of CXCR2 receptor diminishes 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 22 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
neutrophil influx into the lung ( 70-77). In contrast to the multiple CXC chemokines only two CXC chemokines 
receptors, CXCR1 and CXCR2, have been shown to mediate the response to CXC chemokines in human neutrophils. Whereas human CXCR1 binds to CXCL6 and CXCL8 (IL- 8) with a high affinity, human CXCR2 
binds also to CXCL6 and IL -8 as well as several CXC chemokines (GRO -α,GRO -β, GRO- γ, CXCL1, CXCL2, 
CXCL3), ENA -78 (CXCL5) and (CXCL7) ( 78).  
 
M
ECHANISM OF ACTION OF REPARIXIN AS MODULATOR OF THE INFLAMMAYORY CASCADE . Reparixin  (DF1681Y) is 
a specific inhibitor of CXC ligand 8 [CXCL8 ; formerly interleukin (IL)- 8] biological activity, stemming from a 
program of drug design of molecules intended to modulate chemokine action. Reparixin is in vitro a potent and 
specific inhibitor of  CXCL8 biological activity. In vitro chemotaxis experiments have shown that reparixin inhibits 
CXCL8 -induced chemotaxis of human polymorphonuclear leukocytes (PMN ) in the low nanomolar range. Studies 
to elucidate the mechanism of action have shown that rep arixin is a non -competitive allosteric inhibitor of the 
CXCL8 receptors CXCR1 and CXCR2. Interaction of reparixin with CXCL8 receptors inhibits the intracellular signal transduction events activated by binding of CXCL8 to CXCR1 and CXCR2  (85, 86) . In vivo , reparixin 
prevented PMN infiltration into the transplanted kidney and reduced creatinin levels in a rat model of kidney transplantation. Similarly, in a rat model of lung transplantation, reparixin improved isolated graft oxygenation, decreased pulmonary oedema, and significantly reduced neutrophil infiltration into transplanted lungs. Moreover, 
reparixin prevented PMN infiltration and tissue damage in other animal models of ischemia/reperfusion injury of 
liver, brain, intestine, heart and spinal cord. In these models, in vivo inhibition of PMN recruitment ranged from 40 to 90%, and inhibition of tissue damage ranged from 50 to 80%. Efficacy was seen in all models at reparixin dose of 9.90 mg/kg .  
Recently, reparixin lysine salt was evaluated in different m odels of intrahepatic pancreatic islet transplantation in 
mice, which include syngeneic and allogeneic settings. Reparixin was administered by s.c. continuous infusion for 
7 or 14 days starting from day - 1 of islet transplantation. A dose of 5.28 mg/kg/hou r was administered in all 
experiments. Reparixin was able to significantly improve islet engraftment, as demonstrated by its ability to 
increase the likelihood of and to reduce the time to gain non- fasting blood glucose levels less than 200 mg/dl 
(normo -glycaemia) in marginal mass syngeneic islet transplantation model. In the fully mismatched allogeneic 
model, reparixin not only protected islets from early graft failure, but was also able to increase the time to rejection, as shown by post -transplant prolongation of normo- glycaemia. Graft function was indefinitely prolonged in 
20/30% of mice treated with reparixin and rapamycin, suggesting possible tolerance induction. In parallel, reparixin treatment reduced intrahepatic infiltration of PMNs, macrophages, T  helper and dendritic cells  
 R
EPARIXIN EFFECTS ON ACUTE LUNG INJURY (ALI)  MODELS . The therapeutic potential of reparixin  in murine 
models of LPS -induced pulmonary inflammation and acid -induced ALI was studied. Reparixin (15 μg g−1) 
reduced neutrophil recruitment in the lung by approximately 50% in an in vivo model of LPS -induced ALI.  
Reparixin also reduced accumulation of neutrophils in the interstitial compartment  and vascular permeability in 
LPS- induced ALI. Both prophylactic and therapeutic application of Reparixin improved gas exchange, and 
reduced neutrophil recruitment and vascular permeability in a clinically relevant  model of acid -induced ALI ( 70).  
In the CDE (cat dander extract) single challenge model (SCM), administration of Reparixin (15 mg/kg) suppressed neutrophil recruitment into the lungs. In the CDE Multiple Challenge Model, Reparixin inhibited eosinophil, 
neutrophils, and total cell numbers in BALF, serum levels of total IgEand CDE specific IgE, airway epithelial 
mucin secretion, levels of Th2 inflammation‐associated genes periostinand muc5ac, and the BALF levels of IL‐4, IL‐13, IL‐33, and TSLP in BALF.  
 R
EPARIXIN SUPPRESSES ALLERGEN CHALLENGE INDUCED NEUTROPHILIC INFLAMMATION AND ALLERGIC AIRWAY 
INFLAMMATION . In the CDE (cat dander extract) single challenge model (SCM), administration of reparixin (15 
mg/kg) suppressed neutrophil recruitment into the lungs.  In the CDE Multiple Challenge Model, reparixin 
inhibited eosinophil, neutrophils, and total cell numbers in BALF, serum levels of total IgEand CDE specific IgE, airway epithelial mucin secretion, levels of Th2 inflammation‐associated genes periostin and muc5ac, and the 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 23 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
BALF levels of IL‐4, IL‐13, IL‐33, and TSLP in BALF. Pharmacological inhibition of CXCR1/2‐axis by administration of reparixin  inhibits allergen induced innate and allergic airway inflammation in mice ( 79). 
 R
EPARIXIN AMELIORATES THE INCREASED SEVERITY OF PULMONARY FIBROSIS CAUSED BY PARTICULATE MATTER  
In a murine model of bleomycin- induced pulmonary fibrosis, pharmaceutical inhibition of CXCR2 with reparixin 
ameliorated Particulate Matter- induced increased severity of pulmonary fibrosis. Co- treatment with reparixin in 
mice receiving Particulate Matter and bleomycin reduced neutrophil number and neutrophil elastase concentration of day 2- BALF. Moreover, reparixin improved lung function and ameliorated pulmonary fibrosis as assayed by 
total collagen content and histochemical stains of fibrosis markers on day 14- lung tissues. ( 80) 
 R
EPARIXIN  ANALOGUES RESULTED A VALID THERAPEUTIC STRATEGY FOR TREATING LUNG INFECTIONS CAUSED BY 
INFLUENZA A VIRUS OR STREPTOCOCCUS PNUEMONIAE . 
The role of CXCR1/2 during influenza, pneumococcal, and post -influenza pneumococcal infections was 
investigated. Mice were infected with influenza A virus (IAV) or Streptococcus pneumoniae and then treated daily with the CXCR1/2 antagonist DF2162. To study secondary pneumococcal infection, mice were infected with a sublethal inoculum of IAV then infected with S. pneumoniae 14 days later. DF2162 was given in a therapeutic schedule from days 3 to 6 after influenza infection. Lethality, weight loss, inflammation, virus/bacteria counts, and 
lung injury were assessed. CXCL1 and CXCL2 were produced at high levels during IAV infection. DF2162 
treatment decreased morbidity and this was associated with decreased infiltration of neutrophils in the lungs and reduced pulmonary damage and viral titers. During S. pneumoniae infection, DF2162 treatment decreased neutrophil recruitment, pulmo nary damage, and lethality rates, without affecting bacteria burden. Therapeutic 
treatment with DF2162 during sublethal IAV infection reduced the morbidity associated with virus infection and also decreased the magnitude of inflammation, lung damage, and n umber of bacteria in the blood of mice 
subsequently infected with S. pneumoniae. These data suggested that modulation of the inflammatory response by blocking CXCR1/2 improves disease outcome during respiratory influenza and pneumococcal infections, without compromising the ability of the murine host to deal with infection ( 81). 
DF2162, a Reparixin analogue, belongs to the same family of non competitive -allosteric inhibitors of CXCR1 and 
CXCR2 widely characterized in our research labs in terms of structure activity relationship and mechanism of action.  
The two molecules belong to the chemical class of 2 -(R)- phenyl propionamide derivatives thus sharing the same 
chemical moiety.  
Reparixin and DF2162 exhibit similar potency in the inhibition of the target receptors CXCR1 and CXCR2 (IC50s in CXCL8 induced- chemotaxis in the range of 1 nM). The molecular mechan ism of action has been deeply 
characterized by point -mutagenesis studies on CXCR1 and CXCR2 showing that Reparixin and DF2162 bind the 
receptors in the same allosteric site in the Trans -Membrane region, highly conserved in the two receptor subtypes. 
(83-86) 
The different pharmacokinetic profile of the two molecules account for a bid (15 mg/Kg) oral administration of 
DF2162 as compared to a tid (15 mg/Kg) administration (on continuous infusion) for reparixin.  
For this reason, DF2162 has been used to assess the role of CXCR1/2 during influenza  (IAV), pneumococcal, and 
post-influenza pneumococcal infections in mice models. Even though the extensive characterization work was 
conducted with DF2162, preliminary experiments showed a similar behaviour using reparixin in the single IAV model leading to comparable results.  
To investigate the role of CXCR1/2 during influenza infection, mice were infected with 1 × 104 PFU of IAV and then treated three times a day (from day 0  - at the time of the infection  - to day  5 post -infection) with reparixin at 
15 mg/Kg. Similarly to DF2162, treatment with reparixin decreased morbidity, as seen by the reduction of weight loss, reduced leukocytes infiltration into the airways, including neutrophils, and the levels of the pro -inflammatory 
cytokines TNF -α and CXCL1 and reduced the lung injury associated with IAV infection measure by 
histopathological score.  
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 24 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
1.3 Toxicology data 
 Reparixin was tested for toxicity in rodent and non- rodent animal species after single and repeated i.v . doses. The 
repeated dose administration studies were conducted by i.v. continuous infusion, according to the intended human administration route. The general toxicological profile of i.v. R eparixin, in the studies conducted to date, is 
characterized by a low toxicity after single or repeated dose administrations in rats (LD50 = 229.68 mg/kg i.v.; 
660.00 mg/kg/day as No Observed Adverse Effect Level from 4 -week studies) and mice (401.94 mg/kg i.v.). 
Continuous i.v. administration to dogs for 2 weeks resulted in a safe dose of 39.60 mg/kg/day. Continuous i.v. infusion of Reparixin to the male and female rat at dose levels of up to 660.00 mg/kg/day did not have any 
significant adverse effects on mating performance and fertility. Reparixin poses no genotoxic hazard for humans.  
Reparixin lysine salt, at doses in excess of those intended to be used in humans, has a safe pharmacology profile in the renal, cardiovascular and respiratory systems of rats and dogs. The local tolerability of reparixin lysine salt 
was a ssayed in the rabbit ear lateral vein. The compound was well tolerated in concentrations up to 4.95 mg/mL 
(1 mL/kg) infused over a minute. In order to provide evidence of the safety of DF2243Y, the main metabolite of 
reparixin excreted in urine in humans, safety pharmacology and toxicity studies have been performed at doses 2 to 3 times higher that those reached in man, as may occur during the treatment of patients receiving kidney transplantation.  
 
1.4 Pharmacokinetics and product metabolism  
 PK studies by i.v. injection revealed that R eparixin is very rapidly eliminated in rats and humans (t1/2 0.5- 3 hrs 
and 1.0- 1.5 hrs, respectively) whereas elimination is slower in dogs (12- 28 hrs). The PK of reparixin was linear in 
rats and in dogs but linearity was les s evident in humans. Reparixin undergoes complete metabolism (oxidation + 
conjugation) in all the species tested. The in vitro human hepatic, phase I metabolism of R eparixin is catalysed  by 
CYP2C9 and to a lesser extent by CYP2C19. DF2243Y, DF2188Y, methanesulfonamide and ibuprofen are the 
metabolites detected in human plasma and urine, with DF2243Y being the major metabolite. Exposure to ibuprofen 
after administration of R eparixin 2.77 mg/kg/h for 48 hrs (the highest dose tested in humans) was similar or lower 
than that obtained after a standard therapeutic single dose of ibuprofen (300mg). Preliminary PK data obtained in a few patients undergoing islet transplantation shows that plasma l evels of R eparixin (total and unbound) and its 
major metabolite DF2243Y appears to be within the expected range according to the dose administered. Due to extensive metabolism, unchanged Reparixin was poorly or not excreted into the urine of rat, dogs and humans so 
that the PK profile of R eparixin is not influenced by renal impairment. In vitro protein binding of [14C]- reparixin 
showed that R eparixin is highly bound (approximately 99%) to plasma proteins in rats, dogs, rabbits, cynomolgus 
monkeys and humans. Albumin is likely to be the major binding protein in plasma in all species, accounting for 99.2% in humans.   
In clinical trials with oral tablets R eparixin  was administered for 21 consecutive days followed by 7 days of drug 
holyday before the next cycle. Reparixin was rapidly absorbed (median T
max 1 hr). Reparixin systemic exposure 
(Cmax and AUC last) did not change from day 1 to day 21, indicating the absence of accumulation over the dosing 
period. Also t 1/2 did not change from day 1 to day 21, with a median value of about 2 hrs. Once absorbed, R eparixin 
is highly protein bound as only <0.1% to 0.2% of total Reparixin is available as unbound (free) drug. Repa rixin 
was rapidly metabolized to DF2243Y, DF2188Y and ibuprofen. For all three metabolites systemic exposure was similar on both day 1 and day 21 within the observed intersubject variability. The t
1/2 of all three metabolites 
appeared to remain about the s ame from day 1 to day 21.  
To investigate the PK/PD characteristics of Reparixin, we assessed the effect of the drug in inhibiting IL -8-
mediated hPMN NETs release in whole blood of healthy volunteers, 500 µL/sample of whole blood were pre -
incubated with vehicle or different concentrations of reparixin for 15 min at 37°C and next placed onto 13- mm 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 25 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
polylysine coated glass circular coverslips and incubated for 30 min at 37°C in a 5% CO 2 atmosphere to allow for 
cell adherence.  Post-incubation, samples were stimulated with vehicle or IL -8 (100 ng/mL) for 4h (37°C, 5% 
CO 2), after which the supernatant was removed and coverslips washed one time with HBSS. Next, samples were 
stained with 40 nM Sytox Green for 10 min. Finally, cells were fixed in 2% paraformaldehyde and NETs formation determined by confocal microscopy.   Reparixin blocked IL -8-induced NETs formation in a concentration 
dependent manner being the inhibition statistically significant at 5 µg/mL (40% of inhibition) and reaching the 
almost complete inhibition (about 90%) at 25 µg/mL thus confirming that the total blood concentration of 25 
µg/mL (corresponding to a free unbound concentration of 100 nM) that is reached at the steady state by iv infusion or by repeated oral administration (Css) is coherent with  the objective to reach the drug exposure necessary to 
maximize the potential clinical efficacy of the compound.  
Reparixin has some potential in vitro for a non -competitive inhibition of the human hepatic enzyme CYP3A4 that 
is involved in the metabolism of  cyclosporine A, tacrolimus and rapamycin. However, since inhibition is evident 
at concentration far higher than the free plasma concentration of R eparixin at  steady state in humans, it is predicted 
that the clinical relevance of such inhibition is remote.  Indeed, reparixin does not affect to a clinically relevant 
extent the activity of CYP3A4 and CYP2C9 (enzyme involved in R eparixin metabolism), as revealed by an 
interaction study where the PK of midazolam and tolbutamide (probe substrates for these enzyme s) was evaluated 
in healthy subjects receiving single oral doses of the probes alone or in combination with Reparixin.  
 
1.5 Clinical development  
 Reparixin  is the first low molecular weight blocker of CXCL8 biological activity in clinical development.  
Reparixin was granted orphan drug designation for the “prevention of delayed graft function after (solid) organ transplantations” by the European Commission of Orphan Medicinal Products in September 2001 and by the Food and Drug Administration in January 2003. Recently orphan drug designation has been granted in the EU for 
“prevention of graft rejection in pancreatic islet transplantation”. In the 4th quarter o f 2011, Dompé has received 
Scientific Advice from the European Medicines Agency (EMA) for the development of reparixin in pancreatic 
islet transplantation.  
 R
EPARIXIN IMPROVED SURVIVAL AFTER LUNG TRANSPLANTATION . In a US -Canada phase 2 study , 101  
patients (46 on reparixin, 55 on placebo) undergoing single or bilateral lung transplant were trated with reparixin. 
The patients were randomized to receive 48h i.v. continuous infusion (loading: 4.488 mg/kg/h for 30 min, 
maintenance: 2.772 mg/kg/h for 47.5hrs) of either reparixin or placebo starting a few hours before the transplant. The study showed a statistically significant difference in patient survival at Month 12 post -transplant between the 
placebo (7 deaths) and reparixin (no deaths) groups (p- value = 0.0111 [Log -Rank]).  
 
IRCCS
 OSPEDALE SAN RAFFAELE COORDINATED A PHASE 3 INTERNATIONAL TRIAL WITH REPARIXIN IN 
PANCREATIC ISLET TRANSPLANTATION . A phase 3, multicenter, randomized, double -blind, parallel- assignment 
study ([STUDY_ID_REMOVED]) was conducted and coordinated by Ospedale San Raffaele of Milan, Italy in recipients of 
islet allo -transplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Patients received 
either reparixin at a dose of 2.772 mg/kg body weight/h or matched (flow rate/length of infusion) placebo according to their randomization number. Study drugs were administered on top of immunosuppression by 
continuous infusion through a high- flow vein for 7 days starting 12 h before each islet infusion. No clear 
differences between treatment groups were observed for rates, severity, and distribution of AEs or SAEs. Analysis 
of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin, as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression (82). 
CCI
    CONFORMED COPY TO THE ORIGINAL   
 
   Page 27 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
population exposed to i.v. formulation includes 103 adult healthy subjects (100M/3F), 17 patients with different grades of renal impairment (12M/5F), 16 patients  undergoing cardiopulmonary by pass (10M/6F), 46 patients 
undergoing lung transplantation (23M/23F), 48 patients undergoing kidney transplant (31M/17F), 22 undergoing liver transplant (18M/4F) and 85 receiving intrahepatic pancreatic islet infusion (32M/53F), with 22 patients in this group receiving reparixin twice. Exposure included short or prolonged i.v. infusion up to 10.6 mg/kg over 
30min or 133 mg/kg over 48h and, in pancreatic islet and liver transplantation studies, 2.772 mg/kg body 
weight/hour i.v. continuous infusion for 7  days. Overall, reparixin was safe and well tolerated in both healthy 
subjects and critically ill patients. In phase 1 studies, no deaths, Serious Adverse Events (SAEs) or Adverse Event 
(AE)- related withdrawals were reported. The majority of AEs reported were of mild intensity. All subjects had 
recovered completely or had ongoing adverse events of mild intensity when they were discharged. The safety of reparixin was confirmed also in patients with different grades of renal impairment. In the interaction stu dy no 
safety concerns were raised during co -administration of midazolam/tolbutamide with reparixin. During phase 2 
and 3 studies, AE and SAE profile was similar for both placebo and reparixin groups and no particular safety concerns were raised. Data obtai ned in the trials in islet transplantation further support the safety profile of the 
proposed dose, even after a 7 -day administration, repeated twice in several patients. Most frequent ADRs were 
nausea, headache, and vomiting; great majority of these were mild to moderate in nature and none required discontinuation of the Investigational Product. Tachycardia occurred in one patient from Days 5 to 38 after 1st 
islet infusion was judjed probable in relation to Investigational Product. Vomiting, nausea and hea dache on Day 5 
and 6 after 2nd islet infusion in one patient and erythema, nausea and headache on Days 2 to 6 after 1st islet 
infusion in another patient were judged highly probable in relation to the Investigational Product. Nausea, vomiting and severe gastrointestinal bleeding associated with anaemia developed in a female patient early after the beginning of reparixin infusion because the patient received a dose of reparixin 3 times as high as that foreseen in the protocol (medical error). These events were assessed as serious by the investigator and by the Sponsor.  
Overall, the most frequent (>10%) ADRs observed in the phase 1 to phase 3 I.V. studies were: Gastrointestinal 
disorders  (about 26% of the total number of reports), including abdominal pain lower, abdominal pain NOS, 
abdominal pain upper, constipation, diarrhea, dyspepsia, flatulence, gastroesophageal reflux disease, gastrointestinal haemorrhage, intra -abdominal haemorrhage, nausea and vomiting.  
Nervous system disorders  (about 19%), including headache, dizziness, hypoaesthesia, somnolence.  
General disorders and administration site conditions  (about 16%), including cannula site reaction, fatigue, implant 
site haemorrhage, i njection site thrombosis, infusion site oedema, lethargy, malaise, oedema, oedema peripheral, 
and pyrexia   
The patient population exposed to reparixin oral tablets consists of 111 female subjects  receiving either single 
agent reparixin , operable b reast cancer: 20 patients) or the combination of reparixin and weekly 
paclitaxel in metastatic breast cancer : 30 patients;   randomized  61 
patients) . 
In the studies completed so far, reparixin was generally well tolerated  at all doses studied. Overall, 505 ADRs 
were reported in 78 patients in the safety popul ation . 
70.9% of the ADRs were grade 1 (mild), 22.9% were grade 2 (moderate) and 4.3% were grade 3 (severe). One grade 4 ADR was reported overall ( ).  In addition , one patient in clinical trial  experienced 
serious ADRs including grade 4 peritonitis and grade 5 intestinal perforation.  
The most frequent (>10%) ADRs observed in the three studies were:  
Gastrointestinal disorders (31.8%), including nausea, vomiting, abdominal pain, discomfort or distension, dyspepsia, flatulence, constipation.  
General disorders and administration site conditions (16.4%), including fatigue and peripheral oedema . 
 Further data can be found in the Investigator’s Brochure (Appendix 1) 
 
CCI
CCI
CCI
CCI
CCI
CCI
    CONFORMED COPY TO THE ORIGINAL   
 
   Page 28 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
1.7 Phase 2 study  
An open- label, phase 2 study was conducted to assess the efficacy and tolerability of Reparixin  in comparison with 
standard of care. The study included patients with severe COVID- 19 requiring supplemental oxygen, or non-
invasive mechanical ventilation. 51 patients were randomized o verall , 34 in the Reparixin group and 17 in the 
standard of care grou p (2:1 randomization ratio). The primary end- point was the first occurrence of a composite 
endpoint (supplemental oxygen requirement, invasive mechanical ventilation use, admission to ICU, use of a rescue medication for any reason). The treatment with repa rixin was associated with a statistically significant 
improvement in the time to the composite endpoint  (defined as the occurrence of at least one of the following: 
supplemental oxygen requirement,  mechanical ventilation use , admission to I CU, use of a res cue medication for 
any reason) , with fewer days of oxygen use and shorter duration of mechanical ventilation. The results of the study 
suggest that the treatment with reparixin may have prevented the progression to more severe respiratory disease. One deat h occurred in the Reparixin group and three in the control arm. No adverse events were related to 
Reparixin.  
The analysis of the phase 2 data has allowed  establishing proof -of-concept, endpoint selection, and sample size 
planning along with review of Data Monitoring Committee (DMC) recommendations . 
1.8 Phase 3 study  
This phase 3 study has been designed as a double -blind study comparing Reparixin vs placebo on top of the 
standard therapy in the same patient population as that enrolled in the phase 2. Hospitalized patient with severe COVID- 19 pneumonia requiring supplemental oxygen will be randomized. The reference group with placebo is 
justified by the curr ent unavailability of an effective therapy for COVID -19 after having various compounds been 
tested, e.g. remdesivir, hydroxychloroquine, protease inhibitors, tyrosine kinase inhibitors, convalescent plasma or intravenous immunoglobulins. The use of any of these treatments is allowed in the study provided that it is started as background treatment in all patients  characterized by a similar level of disease severity, at a site level .  
2. STUDY OBJECTIVES AND ENDPOINTS  
2.1 Study objectives  
 Efficacy and safety of Reparixin treatment as compared to  placebo (both on top of standard treatment) in adult 
patients with severe COVID -19 pneumonia . 
2.2 Primary Endpoint  
 
-  Proportion of patients alive and free of respiratory failure  at Day 28, i.e. with no need of invasive 
mechanical ventilation or ECMO  or admission to ICU linked to worsening of respiratory parameters 
compared to baseline.   
2.3 Key Secondary Endpoints  
 
- Proportion of patients alive and free of respiratory failure  (as described for the primary endpoint ) at 
Day 60,  
- Mortality rates up to Day  28, 
- Incidence of ICU admission until Day 28,  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 31 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
5.2: Other  treatments ). Follow -up information on the patient’s clinical condition (new hospitalization, need of 
supplemental oxygen, adverse events) and survival will be collected until day 90. 
An interim analysis for efficacy and futility is planned when half of the planned patients has reached the primary endpoint .   
 
3.2 Study population 
Hospitalized adult patients with rt -PCR- confirmed severe COVID -19 pneumonia. Patients are considered to have 
severe disease in the  presence of respiratory distress and requir ing supplemental oxygen. 
No gender and/or ethnicity restrictions will apply.  
 
3.3 Study duration 
The overall study duration is 90  days, including follow -up, but with a variable treatment period.  
The investigational treatment will last up to a maximum of 21 days  (depending the Investigator’s decision based 
on the patient’s condition, or patient decision to withdraw), with a follow -up period lasting up to 90  days since 
baseline.  
The treatment is not foreseen to be continued at home .  
 
3.4 Description of the study  
The study will consist of three study periods: screening, treatment period (up to a maximum of 21 days), follow -
up (up to 90 days).  
During the course of the study, visits and assessments will be performed as defined in the  Schedule of Assessments . 
 Screen ing period  
Patients are included in the study after a variable period at home with initial symptoms of the COVID -19 infection; 
during this period, the patient had supposedly been treated by the family doctor. In case of worsening of his/her general and pul monary condition eventually requiring oxygen supplementation in a hospital environment, the 
patient will start the screening phase for the confirmation of the selection criteria.  
Before any study related procedures, at study entry all patients must have given a written informed consent for the study and will be assigned a screening number . 
Patient meeting all of the inclusion criteria and none of the  exclusion criteria  will b
 e randomized (see section 4.2). 
No time limit has been posed for the time from the  onset of symptoms and hospitalization. No time limit has been 
posed for the duration of the screening period until the treatment start as well. T he time between onset of symptoms 
at home and  the initiation of the investigational treatment, as well as the time  between hospitalization  an
d initiation 
of the investigational treatmentwill have to be recorded.  
If a subject fails screening, the subject may be rescreened once (immediately or later) if deemed appropriate by the investigator. In that case, the subject must be re -consented. A new rescreening period will start and all screening 
procedures must be repe ated.  
 Randomization and treatment   
In order to request randomization to the study, all the pre -treatmen t evaluations must be completed and all the 
inclusion and exclusion cri teria satisfied.  
Consecutive randomisation numbers will be given to the subjects upon their confirmed eligibility for randomization . Subjects will be assigned to their trea tment according to their randomisation number. Pa tients will 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 32 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
be randomized in a 2 :1 fashion between Reparixin and placebo using a computer -generated randomization list 
generated in the study . 
Randomization will be performed through Interactive Response Technology (IRT) . Investigators will have to 
remain blind throughout the whole study duration; sealed envelopes containing information on the actual study treatment to which the patient was randomized (active or placebo) will be provided for emergency use only. Information for unblinding is provided in section 5.1. 
 
Baseline is the day of randomization (stu dy Day 1)  and should possibly be coincident with the start of the 
investigational treatment. End of Treatment (EoT) is the last day of treatment administration .  
The treatment is allowed up to 21 days but it will be interrupted earlier  for the following reasons:   
- Investigator’s decision based on clinical judgment of clinical improvement, even if the patient is still 
hospitalized but no longer requiring supplemental oxygen or significant medical care;  
- occurrence of adverse events;  
- patient’s withdrawal of consent to the treatment.  
During the treatment period assessment visits will be performed at study days 3 - 7 (±1) - 14 (±2) - 21 (±2), or 
until early treatment interruption for any reason.  
An additional visit will be performed on the day of discharge from hospital (or maximum at Day 28 ±2 ) for post -
treatment collection of clinical and laboratory data .  
 Follow -up period  
After discharge from hospital, subjects will be contacted for a follow -up check on their health status at Day 60  
and Day 90 (preferably in person at the Center, or by interview via a telephone call) , unless the patient also 
withdraws the consent to the follow -up.  
For subjects discharged home before the completion of the 21- day treatment period, follow -up visits will be held 
at days 7 (±1) - 14 (±2) - 21 (±2) - 28 (±2) - 60 (±2) and/or 90 (±2) depending on the discharge time point .   
End of Study (EoS) is defined as  the last day the last patient completes the last study assessment (including the 
follow -up assessments), or withdraws the consent to participate in the study, including follow -up. Subjects with 
EoS before Day 28 should undergo a full evaluation (as required on Day 28). Subjects with EoS after Day 28 but earlier than Day  90 should undergo evaluation as required on Day90. 
   
4. STUDY POPULATION 
4.1 Number of patients  
 A total number of 312 subjects will be randomized with a 2:1 randomization ratio ( 208 in the reparixin group; 104 
in the placebo group).  No significant drop- out rate is foreseen which could impact on the number  of the study 
population  
Enrollment can be interrupted at the interim analysys for futility or early efficacy (superiority) of Reparixin over placebo.   
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 33 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
4.2 Inclusion/exclusion criteria  
4.2.1 Inclusion Criteria:  
1. Age 18 to 90, male and f emale subject of any race  
2. Reverse transcriptase Polymerase Chain Reaction ( rt-PCR) -confirmed COVID -19 infection based on a 
nasal / oropharyngeal swab within 10 days before randomization 
3. At least one of the following : 1) Respiratory distress  with tachypnea ( RR ≥ 24 breaths/min  without 
oxygen) ; 2) Partial arterial oxygen pressure (PaO 2) / Fraction of inspiration O 2 (FiO 2), P/F >100 and <300 
mmHg (1mmHg = 0.133kPa), 3) SpO 2 ≤ 94% while breathing ambient air .  
Calculation th rough validated Sat/FiO2 scales is  allowed . 
P/F value of reference if the last available before the signature of consent . 
4. Need of supplemental oxygen  (i.e. new use of supplemental oxygen, or increased oxygen requirement if 
on chronic oxygen) requir ing low - or high- flow oxygen or  non-invasive  mechanical ventilation  (7-point 
WHO -OS category 4 or 5)  
5. Radiological c hest imaging (X -rays, CT scan) confirms lung involvement and inflammation (presence of 
ground- glass opacities,  and/or  inter/intra lobular septal thickening, and/or consolidations in a patchy 
distribution ).  
6. Inflammatory status as documented by at least one of the following: Lactate dehydrogenase (LDH) > normal range,  C-reactive protein (CRP) ≥ 100 mg/L , IL-6 ≥ 40 pg/mL, serum ferritin ≥ 900 ng/mL, XDP 
> 20 mcg/mL.  
7  Females  of child -bearing potential and with an active sexual life must not wish to get pregnant within 30 
days after the end of the study and must be using at least one of the following reliable methods of contraception:  
v) Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after final visit  
vi) A non- hormonal intrauterine device [IUD] or female condom with spermicide or contrace ptive 
sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after final visit  
vii) A male sexual partner who agrees to use a male condom with spermicide  
viii) A sterile sex ual partner  
Female participants of non -child -bearing potential or in post -menopausal status for at least 1 year will be 
admitted. For all female subjects, with child -bearing potential, pregnancy test result must be negative 
before first drug intake.  
 
4.2.2 Exclusion Criteria:  
1. Cannot obtain informed consent.  
2. hepatic dysfunction with Child Pugh score B or C, or ALT or AST> 5 times the upper limit;  
3. renal dysfunction with estimated glomerular filtration rate  (MDRD)  <  5 0  m L /min/1.73 m2 or patient 
receiv ing continuous renal replacement therapy, hemodialysis, or peritoneal dialysis . 
4. Bacterial sepsis  (besides COVID -19 sepsis) 
5. Positive test for influenza virus, if tested during the current illness ( note: influenza testing is not required 
by protocol)  
6. Known congenital or acquired immune deficiency ,  
7. Patients with hypersensitivity to ibuprofen or to more than one non- steroidal anti- inflammatory drug or 
to more than one medication belonging to the class of sulfonamides (e.g. sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib ).  
Hypersensitivity to sulphanilamide antibiotics, e.g. sulfamethoxazole, does not qualify for exclusion.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 34 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
Know allergy to any medication (either investigational or non- investigational) which is planned at study 
entry for u se during the study.  
8. Patients receiving other not allowed medications ( see Section: Not allowed medications ) 
9. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment.  
10. Evidence of COVID -19 disease progression during previous ly initiated  treatm ent with remdesivir (alone 
on in any combination with other antiviral treatments), protease inhibitors (e.g. ritonavir, lopinavir, darunavir – atazanavir) , tyrosine kinase inhibitors (e.g. baricitinib, imatinib, gefitinib) , convalescent 
plasma or intravenous immunoglobulin for COVID -19, or investigational treatments  
11. More than three infusions of remdesivir, including the loading dose , prior to randomization  
12. Subject participating in other interventional clinical trials. Subject having received investigational therapy 
in the previous 3 days, or at least 5 half -lives.  
13. At the time of enrollment, patients not in a clinical condition compatible with the oral administration of the study drug.  
14. P/F < 100 mmHg  
15. Pregnancy:  
i) positive or missing pregnancy test before first drug intake or day 1;  
ii) pregnant or lactating women;  
Women of childbearing potential and fertile men who do not agree to use at least one primary form of  
contraception for the duration of the study.  
 
 
5. TREATMENTS 
5.1 Investigational product s 
5.1.1 Dose regimen and administration  
Patients who satisfy the predefined inclusion and exclusion criteria for this trial will be randomized at a 2:1  ratio 
to one of the following treatment groups:  
 
- Group 1:  Reparixin oral tablets , 1200 mg three times daily ( TID) (2 tablets 600 mg each, TID)  for up 
to 21 days or until decision of discharge from the hospital, on top of standard supportive care .   
 
- Group 2 (control):  placebo , 2 tablets TID  (identical to Reparixin tablets) for up to 21 days or until 
decision of discharge from the hospital, on top of standard supportive care .  
No dose modifications are allowed.  In case of significant adverse events which are supposed to be possibly / 
probably related to Reparixin, the study drug may be temporarily interrupted (and eventually resumed at the 
stand ard dose / schedule, if considered safe for the patient), or definitively withdrawn.  
Because the blinded condition does not allow the Investigator to know the actual treatment in a given patient, any 
decision will be made assuming that the concerned treat ment is Reparixin.  
 For each administration , two tablets  of Reparixin (600 mg  each) or placebo will be taken , for the total of three 
daily administrations  (6 tablets daily). It is advisable to take the tablets with a glass of water to facilitate 
swallowing.  
For patients who are unwilling or unable, in the opinion of the investigator, to comply with the oral tablet treatment, is possible to continue the regular administration of the study drug by administering  the medicine through a naso-
gastric tu be, following this procedure: for each administration, disperse two Reparixin 600 mg tablets in 25 mL of 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 35 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
drinking water in a suitable container (e.g. conical tubes for 50 mL Falcon centrifuge). Disgregate the tablets (shaking manually or with the aid of a planetary shaker or a rocker) until obtaining a homogeneous milky suspension (time required 7 - 10 minutes). Keep the prepared suspension at room temperature and protected from 
light for up to 24 hours. Immediately before administration, manually shake the  suspension again until complete 
and homogeneous resuspension, withdraw using a 50 mL needle -free syringe and administer to the patient using 
a naso -gastric tube. After administration, run 25 ml of drinking water through the gastric tube.  
 The use of the study drug not in accordance with th is protocol  could constitute a protocol violation.   
The use of the study drug outside this protocol is not allowed.  
 
5.1.2 Randomization 
Randomization will be performed through an Interactive Response System (IRS). Specif ic procedures for 
randomization through the IRT are contained in the study procedures manual.  
Each Patient’s treatment pak/ Kit number will be randomly associated with a treatment group. The randomization 
list will be provided to the facility responsible for IMP packaging/labelling for the purpose of IMP preparation. Each randomized patient will be allocated with randomization number according to the stratified randomization list. Dropouts after randomization will not be replaced  
Randomization will be stratified by site, gender and age class (<65 yrs vs ≥ 65 yrs) to ensure balanced assignment 
across treatment groups. The stratified permuted block randomization list will be generated with a computer procedure by an independent statistician not involved in the conduct of the study.  
 
5.1.3 Unblinding   
For each randomized subject, individual code breaks will be accessible in the event of a medical emergency requiring knowledge of the treatment assigned to the subject. Only the responsible investigator, or authorized delegates, can break the code via the IRT or by opening the sealed envelopes with indication of the actual treatment . 
Describe unblinding procedure -to be modified based on study specific process.  
(Paper envelope unblinding) Individual treatment codes will be provided as a tamper -resistant syst em (either a 
sealed envelope or a scratch card) to:  
-     the Investigator for emergency procedures;  
-     the Dompé Drug Safety for safety procedures.  
Individual treatment codes must be kept in a secure location accessible only to designated staff in order to prevent 
dissemination of the treatment to personnel involved in study conduct who must remain blind.  
During the study the integrity of the envelopes will be regularly checked by [CRO] Monitor during the visits at 
site. At the end of the study all th e individual envelopes must be returned to Dompé. A copy of the Individual 
envelopes identified with the subject assignment number will be also sent to the Dompé Pharmacovigilance Responsible.  
Any breaking of the treatment code by the investigational staff must be reported immediately to the Sponsor  and 
must include an explanation for breaking the code. The sponsor should be contacted to discuss the case, if 
possible, prior to unblinding.   
A general rule is that breaking the code is only allowed if the knowledge of the actual treatment is necessary for an appropriate decision on actions / treatments for the safety of the patient.  
The DMC will have access to group -unblinded and/or fully unblinded DMC reports.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 36 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
The sponsor ’s personnel from the Pharmacovigilance Department  of Dompè may break the treatment code for 
subjects who experience a Suspected Unexpected Serious  Adverse Reaction (SUSAR), in order to determine if 
the individual case requires expedited regulatory reporting. Pharmacists will be provided with the ‘Instructions to the Pharmacy’.  
Investigators will be allowed to unblind study medication directly through the IRT system and must notify CRO’s medical monitor. Training is provided to  investigators prior to authorization to use the IRT system and the 
unblinding function is outlined in the study specific user guide.  
The randomization code will be broken when the last enrolled patient has completed therapy, and once the database has been locked.  
 Unblinding can only occur in case of emergency, when knowledge of the treatment identity is essential for treating 
the subject.  
If the treatment code needs to be broken in the interest of patient safety for a medical emergency, the Investigator 
is allowed to break the treatment code for the specific patient, even before informing the Sponsor. The Investigator must always notify the Sponsor, so that the reason for any premature unmasking can be documented, by means of a communication to CRO/Dompé Pharmacovigilance to the contact details in the section “Contact Information” 
and to Dompé Medical Expert.  
The Investigator will inform the Dompé representative (Dompé Medical Expert) if an emergency unmasking was performed without revealing the treatment identity, but only referring to the kit number involved in the unmasking in order to avoid a dissemination of unmasked information.  
Dompé Pharmacovigilance  will unmask patient treatment only for safety reason and will document envelope 
opening or unblinding through the IRT system.  
Additionally, Dompé Pharmacovigilance  may need to unmask the patient’s treatment if a reported SAE meets 
criteria of a Suspected Unexpected Serious Adverse Reaction (SUSAR) in order to fulfill expedited regulatory reporting requirements. Unmasked information shall not be disclosed to Investigators.  
The identity of the treatments will remain unknown to the subject, Investigator, site staff, CRO and Dompé’s Development personnel until the study completion and formal unmasking.  
 
5.1.4 Compliance to Treatment  
The actual  doses of the study drugs received by each patient during the trial will be recorded.  A reconciliation will 
be made by the study monitor between expected and actual administrations over the time between baseline and EoT. Discrepancies will have to be documented and justified.  
  
5.2 Other treatments  
5.2.1 Additional therapy  
 Any additional  therapy must be considered as local standard of care treatment, and it  must be able to be 
administered  to all patients enrolled in the study. I nvestigators are allowed to provide any medications having 
received final or conditional approval for the treatment of the COVID- 19 infection, or used off -label at the 
Investigator’s discretion  and justified by scientific evidence of effectiveness against the COVID- 19 infection  
without to stop study treatment.  
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 37 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
5.2.3 Concomitant and not allowed medications  
No specific wash -out is required for treatments (symptomatic treatment for COVID -19, or any therapy for 
concomitant diseases) which are ongoing at screening, unless decided by the Investigator.  
During hospitalization, patient will receive the standard suppor tive care based on the patient’s clinical need, 
eventually including anticoagulants, corticosteroids, antibiotics, among others, as per local standard therapy and in line with international guidelines. Optimal oxygenation can be considered an SpO
2 between 92% and 96%; 
however, no specific oxygen target is required by the protocol.  
The Investigator’s intention to adopt a supportive use of other specific COVID -19 treatments , available off-label 
or under conditional or final approval [ for example: remdesivir (± baricitinib), hydroxychloroquine, protease 
inhibitors (e.g.  lopinavir / ritonavir, darunavir – atazanavir), tyrosine kinase inhibitors (e.g. baricitinib, imatinib, 
gefitinib), convalescent plasma or intravenous immunoglobulin] should be discussed with the  Sponsor’s Clinical 
Operations . This  preventive measure may be allowed only if that medication is routinely used at the site as a local 
standard of therapy, there is guarantee that it will be available during the whole duration of the study and it will be uniformly applied to all the study patients to be enrolled at that Center  in this protocol  characterized by a similar 
level of disease severity, at a site level .  
 Any concomitant medication that the participant will be receiving during t he participation in this study will be 
recorded  in the CRF with annotation of whether the medication is considered a specific “standard of care” for the 
treatment of the COVID -19. Dose, schedule of administration, start and end date, and reason of use will  be 
collected. In case of complex schedules of administrations or variable intraday dosing (as those possibly in use in the ICU) an estimated, consistent, average dose can be reported, if also recorded in the source documents.  
 There is no contraindication to the use of  concomitant supportive and prophylactic care medications as deemed 
necessary by the treating physicians, unless a significant drug -drug interaction leading to metabolic alterations and 
potential harm to the patient is suspected based on the respective metabolic pathways . Reparixin is catalysed by 
CYP2C9 and to a lesser extent by CYP2C19.  Reparixin has some potential in -vitro for a non -competitive inhibition 
of the human hepatic enzyme CYP3A4.    
However, at the present time, clinically significant untoward pharmacological interactions are not known for reparixin .  
A list of medications known to act as inhibitor or inducer  of CYP2C9  is provided hereafter : 
- CYP2C9 Inducers : rifampin, carbamezapine, aprepitant, bosentan, phenobarbital, St. John’s Wort;  
- CYP2C9 Inhibitors: amiodarone, fluconazole, miconazole, oxandrolone, capecitabine, cotrimoxazole, 
etravirine, fluvastatin, fluvoxamine, metronidazole, sulfinpyrazone, tigecycline, voriconazole, zafirluk ast. 
 
For remdesivir (recently receiving conditional approval for the treatment of COVID- 19; June 2020) no clinical 
interaction studies have been performed and t he overall potential of this drug for interactions is currently unknown. 
However, reparixin is not a substrate of the microsomal enzymes of which remdesivir is an in-vitro  inhibitor 
(CYP3A4, OATP1B1 , OATP1B3 ) or inducer ( CYP1A2 , CYP3A) .  
Reparixin  was found to slightly inhibit human CYP3A4 but only at very high unbound drug concentration of (IC50 
8 µM), concentration significantly higher than the concentration of unbound drug reachable with the proposed 
administration regimen.  
Furthermore, recent expert reports suggest remdesivir exposures unlikely to be substantially affected by CYP3A4, 2C8, or 2D6 isoenzymes or by P -gp or OATP drug transporters and the drug may be administered with weak to 
moderate inducers or with strong inhibitors of these CYP isoenzymes or drug transporters. However, because strong inducers may modestly reduce remdesivir exposures and clinical relevance of lower exposures is unknown, experts state that concomitant use with drugs that are strong inducers (e.g., rifampin) not recommended
 (reference 
attached.  

CONFORMED COPY TO THE ORIGI NAL  
Page 39 of 66 
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
keep a cumulative inventory and records  of dispensing, use or loss of study drug. A reconciliation will be done 
between  delivery and used / returned medication. Any discrepancies must be accounted for and documented.  
At the end of the study and after drug accountability has been conducted by the Sponsor or representative , partially 
used or unused study drug should be disposed for desctruction operated by the local inestigational  site according 
to their procedures (documentation of destruction provided to Dompé farmaceutici) , or returned to Dompé 
farmaceutici,  as agreed between the parts .  
Drug returns have to be performed before the drug’s e xpiry date.  
6. DISCONTINUATIONS
End of treatment (EOT) definition: EO T is defined as the last treatment day in a randomized patient. EOT occurs 
upon completion of the scheduled treatment period (up to 21 days)  for clinical judgment of improvement , or at the 
time of discharge from hospital, or at any time the treatment is terminated early for any reason (e.g. for adverse 
events, ineffectiveness, withdrawal of consent for treatment). Patients randomized but with no actual treatment 
ever initiated, will have  their EOT and EoS on the date of randomization.  
Patients who discontinue the treatment will not be withdrawn from the study by default, but  will be asked to 
complete safety and efficacy observations as per the protocol, unless otherwise they withdraw their consent.  
End of study (EOS) definition: EOS  is defined as the last day the last patient completes the last study assessment 
(including the follow -up assessments), or withdraws the consent to participate in the study including refusal to 
undergo follow -up, or is deceased or otherwise lost to follow -up.  
Discontinuation and withdrawal  
A patient has the right to withdraw from this clinical trial at any time and  for any reason, without  any repercussion.  
Investigator s also have the right to withdraw a patient from the study at any time  if in their opinion it is no  longer 
in the best interest of the patient to remain in the study.  
The patient has no obligation to give a justification for his decision to withdraw from the study, however, the 
Investigator should investigate the reason, as far as possible, and record it in the CRF. The primary, actual, reason of withdrawal should be recorded, especially if there is supect of withdrawal due to adverse events (“withdrawal of consent” is a definition to be used if the patient does not give reasons). Notifications will be made to the regulatory authorities of study withdrawals for safety reasons and for any DMC decision to pause enrollment or 
terminate the study , according to the local country regulations.  
Participants who withdraw from the study cannot be re -randomized and are not replaced by another subject.  
All discontinuations must be recorded by the investigators; they should be promptly reported to the Sponsor if due to serious adverse events. In case of treatment discontinuation, an EoT  visit should be conducted and data recorded; 
in case of withdrawal fr om the study, an EoT  and/or EoS visit should be conducted.  
Patients will be followed -up according to the study procedures set forth in this clinical trial protocol and until the 
scheduled last day of follow -up (day90 ). The only exception will be the collec tion and reporting of AEs that have 
occurred during the clinical trial and have not resolved by the time of the end of follow -up: in this case AEs will 
be followed until resolution or stabilization.  
Stopping criteria for individual subjects   
Subjects should be prematurely discontinued from study treatment for any of the following reasons:  

CONFORMED COPY TO THE ORIGI NAL  
Page 40 of 66 
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
•subject no longer consents to participate in the treatment phase of the study, yet consenting for the
continuation of the collection of information in the follow -up phase of the study (specific consent to be
signed).
Patient may eventually decide to withdraw the consent for the study continuation  including the collection
of information in the follow -up phase,
•physician decision that it is in the best interest of the subject to be discontinued from study treatment ,
•physician decision because of poor efficacy or poor tolerability of the investigational treatment,
•the treatment will be interrupted in case of significant worsening of the renal function with eGFR(MDRD) falling to below 30 ml/min/1.75m
2 or an increase of serum creatinine by more than 50% since
randomization , either due to the study drug (or other concomitant drugs)  or to the progression of the
underlying disease ,
•severe protocol deviations , e.g. in relation to the inclusion / exclusion criteria, major treatment
uncompliance (> 3 days of unjustified missed treatment), major procedural uncompliance (notably, themissed collection of information for the determination of the study primary end- point) .
All study subjects, including treatment discontinuations for any reason, will have to be followed up until the End 
of Study, unless the patient withdraws his/her consent to the study continuation including the follow -up.  
Stopping criteria  for the clinical trial:   
The Sponsor may terminate this study prematurely, either in its entirety or at any study site,  for reasonable cause 
provided that written notice is submitted in advance of the intended termination. Advance notice is not required 
if the study is stopped due to safety concerns.  
The recommendations of the Data Monitoring Committee  will be taken into consideration in this regard.   
If the Sponsor terminates the study for safety reasons, the Sponsor will immediately notify the  investigator and 
subsequently provide written instructions for study termination.  
7. ASSESSMENTS AND PROCEDURES
7.1 Procedures  
Potential study patients with confirmed COVID -19 diagnosis will be identified from those referring to the 
participating clinical sites for diagnosis and/or management. Screening will be performed and completed in consented patients and any suitable  study patients will be treated. All subjects sign ing the informed consent form 
and screened for the present study will be coded with “unique subject identifiers”  (see section 11. 6).  
Each patient will be involved in the study for the entire duration of the hospit al treatment and for a maximum of 
90 days since randomization and including the follow -up. 
Patient should not be screened if, for any reason, there is a high probability that he/she will be transferred during the treatment phase to another institution (administratively separated from the investigational site) not belonging to this study network. Should this occur, the patient will be withdrawn from the study. If the randomized patient is transferred to another already opened study center, the responsibility for the patient treatment and management 
will be assumed by the new Principal Investigator. Agreements will have to be made with the Sponsor for the 
provision of the study material for that patient.  
During the study, the results of all required clinical, laboratory, instrumental examination will have to be reported 
in the eCRF (date of the test, outcome, units).  Original data have to be kept in the patient’s hospital files and made 
available to the clinical monitor of the study for quality checks.  
Clinic al examinations will be performed by the Principal Investigator or authorized sub- Investigator or nurse.  

CCI
CCI
    CONFORMED COPY TO THE ORIGINAL   
 
   Page 46 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.  
Adverse Drug Reaction  
An Adverse Drug Reaction (ADR)  is defined as an adverse experience which is reasonably likely to have been 
caused by the drug.  Adverse events are to be considered unsuspected if the relationship to the study drug as 
described in the table in section 7.3.4 is none or unlikely; whereas any AE reported in the study having a possible, 
probable or highly probable relationship to study drug will be considered as an ADR. The definition covers also medication errors and uses outside what is foreseen in the protocol, including misuse and abuse of the product.  
Serious Adverse Event  
A Serious Adverse Event ( SAE ) is defined as any untoward medical occurrence that at any dose:  
• results in death,  
• is life -threatening (i.e. the patient was at risk of death at the time of the event. It does not refer to an event 
which hypothetically might have caused death if it were more severe),  
• requires inpatient hospitalization or prolongation of existing hospitalization,  
NOTE: In general, hospitalization means that the individual remained at the hospital or emergency ward for obser vation and/or treatment (usually involving an overnight stay) that would not have been appropriate in 
the physician's office or an out -patient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred, the event should be considered serious.  
• results in persistent or significant disability/incapacity,  
NOTE: This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions, but do not constitute a substantial disruption.  
• is a congenital anomaly/birth defect,  
• is medically significant or important medical condition, i.e. an important medical event that based upon appropriate medical judgment, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above.  
An important medical condition is an event that may not result in death, be life -threatening, or require 
hospitalization but may be considered a SAE when, based upon appropriate medical judgment, it may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in patient hospi talization, or 
the development of drug dependency or drug abuse.  
Death shall always be reported as SAE: anyway, d eath due to progression of disease would not have a causal 
relationship to the product , based on Investigator’s assessment . The investigator should report the event 
immediately to the sponsor, but the sponsor will not report the event as expedited to regulatory authority. Cause of death shall always be specified when known.  
Unexpected Adverse Events  
An AE or ADR is considered unexpected if it is  not listed in the Investigator Brochure (Reference Safety 
Information section) or in the applicable authorised Summary of Product Characteristics. An event is unexpected also when it is not listed at the specificity or severity that has been observed and listed in the Investigator Brochure. 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 47 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
Events that are mentioned in the Investigator Brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation are considered unexpected.  
The determination of expectedness shall be made on the basis of the IB Reference Safety Information (RSI) section.  
Suspected Serious Unexpected Adverse Reaction  (SUSAR)  
A suspected serious unexpecte d adverse reaction  is defined as an adverse reaction that is both unexpected (not 
consistent with the applicable product information) and also meets the definition of a Serious Adverse Reaction.  
 
8.2 M onitoring for adverse events   
During the study,  the subject shall have  the opportunity to spontaneously mention any problems  and anyway the 
Investigator or appropriate designee should inquire about AEs by asking the standard questions:  
• “Have you had any health problems since your last study visit?”  
• “Have there been any changes in the medicines you take since your last study visit?”  
AEs should be reported for any clinically relevant change in concomitant condition(s) that is the result of an 
untoward (unfavorable and unintended) change in a subject’s medical health, regardless of causality . Changes in 
any protocol -specific systemic parameter evaluated during the study are to be reviewed by the Investigator.  
8.3 Recording  of adverse events  
AEs will be collected and recorded for any untoward event that occurs in a patient from the time he or she signs 
the Informed Consent  for the trial until the end of the follow up period. Thus, any untoward medical occurrences 
or unfavorable and unintended signs, symptoms, or diseases that occur in the pretre atment, in treatment, or post 
treatment period are to be considered AEs and/or SAEs, and consequently recorded and reported as such. Should 
a non- serious AE become serious, the Investigator will then follow the same reporting procedures as for SAEs.  
Each A E will be described by:  
• Its duration (start and stop dates).  
• Its seriousness. 
• Its relationship to the study drug (suspected/unsuspected).  
• Action(s) taken.  
• Outcome.  
Medical conditions/diseases  and related signs/symptoms present before starting study treatment shall be 
documented in the medical history section of the CRF; these conditions are considered AEs only if they increase either in frequency or severity once informed consent has been signed.  
 
8.4 Relationship and severity of AEs to the Investigational product 
The Investigator will assess the possible relationship between the AE and the investigational medication, according to the criteria in Table below:  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 48 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
Relationship of the Adverse Event to t he IMP  
None (Intercurrent 
Event) An event that is not and cannot be related to the Investigational Product, e.g. patient is a passenger in a road traffic accident .  
Unlikely (remote)  Relationship is not likely e.g. a clinical event including laboratory test 
abnormality with temporal relationship to drug administration which makes 
a causal relationship improbable and in which other drugs, chemicals or 
underlying disease provide more plausible explanations 
Possible Relationship may exist, but c ould have been produced by the patient’s 
condition or treatment or other cause 
Probable Relationship is likely, the AE abates upon discontinuation of Investigational Product and cannot be due to the patient’s condition 
Highly Probable Strong relationship, the event abates upon discontinuation of Investigational 
Product and, if applicable, re-appears upon repeat exposure 
 
The Investigator will grade the severity of any AE according to the National Cancer Institute Common 
Terminology Criteria f or Adverse Events (NCI CTCAE) toxicity grading scale, version 5.0, as per definitions in 
the Table below. For each episode, the highest severity grade attained should be reported.   
Grading scale  of the Adverse Event  
 
Grade 1  Mild; asymptomatic or mild symp toms; clinical or diagnostic observations 
only; intervention not indicated . 
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL *. 
Grade 3  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self care ADL **. 
Grade 4  Life-threatening consequences; urgent intervention indicated. 
Grade 5  Death r elated to AE.  
*Instrumental Activities of Daily Living (ADL) refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc.  
**Self -care ADL refer to bathing, dressing  and undressing, feeding self, using the toilet, taking medications, and not bedridden.  
 
8.5 Follow- up of patients with adverse events  
The Investigator is responsible for adequate and safe medical care of subjects during the trial and for ensuring that 
appropriate medical care and relevant follow -up procedures are maintained after the trial. All AEs should be 
followed -up to determine outcome of the reaction. The Investigator should follow up the event until resolution or 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 50 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
•  Abnormal  values or test results that do not induce clinical signs and/or symptoms and require 
intervention/therapy, i.e. are clinically significant.  
 Adverse Events Exemption 
 
Not applicable. There is no event to be considered routinely associated to any clinical study  procedure , 
therefore requiring neither recording nor reporting. 
 
 
Reporting procedure of safety information  
SUSAR expedited reporting to Regulatory Authorities  and ECs   
The Investigator shall report all serious adverse events immediately to Dompé Pharmacovigilance and Clinical Operations and to the CRO contact, as described in Section 7.3.6 . 
The Investigator shall notify SAE to his/her EC as applicable; in addition, f or reported deaths of a subject, the 
Investigator shall supply Dompé Pharma covigilance and Clinical Operations /CRO Monitorand the Ethics 
Committee with any additional information requested.  Copies of all correspondence relating to reporting of any 
SAEs to the EC  should be maintained in the Investigator’s Files.  
 Dompé Pharmacovi gilance  shall submit  any serious unexpected ADR (SUSAR) to the concerned EC  and 
Regulatory Authority (via Eudravigilance Clinical Trial module)  which approved the study,  as soon as possible 
and in no event later than:  
• seven calendar days after becoming aware of the information if the event is fatal or life threatening; to be followed by any relevant information within eight days.  
• fifteen calendar days after becoming aware of the information if the serious event is neither fatal nor life threatening.  
 Dompé Pharmacovigilance  shall report any relevant updated follow -up safety information as soon as available.  
If the results of an investigation show that an ADR  not initially determined to be reportable is reclassified as 
reportable, Dompé Pharmacovigilance shall report such reaction in a written safety report as soon as possible, 
within the timeframes defined by current law requirements . 
Treatment will be unblinded by Dompé Pharmacovigilance prior to regulatory submission of a SUSAR 
to Regulatory Authorities and ECs and only cases referred to active treatment will be considered 
expeditable for regulatory reporting, in line with law require ments.  
Periodical Reporting to Regulatory Authorities , ECs and Investigators   
Dompé shall be responsible to prepare and submit annual safety reports (Development Safety Update Report – 
DSUR) to relevant Regulatory Authorities, as applicable.  In addition, I nvestigator will receive from Dompé 
Pharmacovigilance appropriate periodic safety updates , as per applicable local requirements and regulations.   
 
8.7 Exposure to investigational product during pregnancy  
 
Any pregnancy detected at screening  leads to the immediate exclusion from the trial.  
 
CCI

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 51 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
8.8 Adverse events causing treatment discontinuation  
If a patient is withdrawn from the study as a consequence of an AE, this must be recorded and reasoned in the CRF, and the patien t must be followed up until the resolution of the AE or as instructed by the medical monitor.  
 
8.9 Overdose  
Cases of overdose (accidental or intentional) which may or may not result in serious adverse  reactions are to be 
reported to Dompé Pharmacovigilance and Clinical Operations /CRO Monitor , following the same procedure for 
SAE, within 24 hours from the Investigator’s knowledge of its occurrence. The Medical Expert should be contacted 
to discuss corrective treatment, if necessary.  
An overdose of the stu dy drug  is defined as : 
- Tablets: The administration of 3 or more additional tablets on any given treatment day  
- IV formulation: The administration of more than 50% of the daily dose.  
Overdose includes reports related to drug intake through different routes (e.g. ingestion) or with suicidal intentions and consequent drug overdose.  
The Investigator shall provide in the SAE form information about symptoms, corrective treatment and outcome of 
overdose.  
   
9. DATA MONITORING  COMMITTEE  
 
An independent Data Monitoring Committee (DMC)  will be appointed with the responsibil ity of safeguarding  the 
interests of trial participants, assessing the safety and efficacy of the interventions during the trial, and monitoring 
the overall conduct of the  clinical trial.  These tasks will be accomplished  on an ongoing basis throughout the trial . 
The DMC will provide recommendations about stopping or continuing the trial. In order to contribute to enhancing the integrity of the trial, the DMC may also formulate recommendations relating to the selection/recruitment/retention of participants, their management, improving adherence to protocol -specified 
regimens and retention of participants, and the procedures for data management and quality control .  
 The DMC w ill be advisory to the clinical trial leadership group  (the Scientific Committee  of the study) . The 
Scientific Committee will be comprised of the sponsor’s study team and lead study investigators, who jointly will have responsibility for the design, conduc t and analysis of the clinical trial. The Scientific Committee will be 
responsible for promptly reviewing the DMC recommendations, to decide whether to continue or terminate the 
trial, and to determine whether amendments to the protocol or changes in the study conduct are required.  
 
  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 52 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
10. STATISTICAL CONSIDERATIONS  
10.1 Sample size 
The sample size of the study is calculated based on results from the phase II, open label REPAVID -19 study. 
Considering a randomization ratio 2:1 (Reparixin:placebo) and a one -sided alpha of 0.025, a total of 264 evaluable 
patients will allow to achieve a n overall  power of 90% to detect a group difference  ≥20% in proportion of patients 
alive and free of respiratory failure at Day 28 in favor of reparixin, assuming that the proportion of patients  alive 
and free of respiratory failure in the placebo group will be approximately 60%.  
Sample size has been adjusted in order to take into consideration an interim analysis during the study. Details on interim analysis are provided in section 10.4. 1. No additional multiplicity correction of alpha is required.  
Assuming that 15% of subjects will not be evaluable for primary analysis, a total of approximately 31 2 subjects is 
expected to be enrolled.  
10.2 Overview  of planned statistical analyses 
The study plans for the following statistical analyses:  
• Interim analysis for efficacy or futility: this analysis will be conducted by an independent statistician 
when half of the evaluable patients has reached the primary endpoints at Day 28  (details in section  10.4. 
1); 
• Key first efficacy analysis: this analysis will be conducted by an independent statistician when all enrolled 
patients are evaluable for the primary analysis at 28 days  and the database has been interim locked ( details 
in section  10.4.2) ;  
• Final analysis: this analysis will be conducted when all enrolled subjects have completed the study and the study database has been unblinded and locked; 
• Analyses for the Data Monitoring Committee: these analyses will be produced periodically according to the DMC charter . 
 
10.3 Analysis Population 
The following population will be defined:  
• The Safety (SAF) population will consist of all randomized patients who received at least one dose of the investigational product. Safety population will be analyzed according to the actual treatment received. The SAF population will be used to present res ults on safety data.  
• The Full Analysis Set (FAS) population will consist of all randomized patients who received at least one dose of the investigational product. FAS population will be analyzed according to ITT principle, i.e. by 
treatment allocation. The  FAS population will be used for the primary analyses of the study and to present 
results on efficacy data.  
• The Per Protocol (PP) population will consist of all randomized patients who received at least one dose 
of the investigational product and do not have Major Protocol Deviations. The PP population will be used for sensitivity analyses.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 54 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
10.5 Statistical Methodology 
10.5.1 General Considerations  
Appropriate descriptive statistics will be produced by treatment arms according to the nature of the variable.  For 
continuous data, number of observations, mean, standard deviation, median and range (minimum and maximum) will be presented.  For qualitativ e data, frequency distributions and percentages per category will be presented.  If 
appropriate, confidence intervals around the mean or the proportions will be presented. The number of subjects with missing data will be presented under the “Missing” categ ory. Missing values will not be included in the 
denominator count when computing percentages. When continuous data will be summarized, only the non -missing 
values will be evaluated for computing summary statistics. Any exception will be declared.  
For time -to-event variables, cumulative freedom from event will be evaluated using Kaplan -Meier method. The 
degree of uncertainty will be expressed with 95% confidence limits (calculated per the method proposed by Greenwood). Comparison of curves among arms will be performed with the log- rank test. Kaplan -Meier graphs 
will be presented along with the number of patient -at-risk at exact time points. Subjects who are free from event 
at the time of DB lock will be censored at the DB lock date. Reasons for discontinuation  will be incorporated into 
the analysis for determining censoring and failure  status. Specifically, study discontinuation for Adverse Event, 
Death, Lost to follow -up or other negative outcomes will be considered as failure events. Subjects who have 
disco ntinued for other reasons without an event will be censored at the date of discontinuation.  
Unless otherwise specified, the significance level used for statistical testing will be 0.05 and two -sided tests will 
be used. All patient data collected on the CRF  will be listed by patient and centre.  
The Statistical Analysis Plan will be issued before the interim analysis and database lock  with more technical and 
detailed elaboration of the principal features of statistical analyses. Additional post- hoc analysis may be produced 
to further allow comparison between treatment and control, according to the results obtained. Any deviations from the original statistical plan (including unplanned analyses) will be documented in the Clinical Study Report.   
 
10.5.2 Analys is of efficacy variables  
10.5.2.1 Primary analysis  
The following null hypothesis is defined:   the proportion of patients alive and free of respiratory failure  at Day 28  
(see section  2.2 for details ) in reparixin  is lower or equal than control:  
 
H0: TREPARIXIN  ≤ T CONTROL  
H1: TREPARIXIN  > T CONTROL  
where T REPARIXIN  and T CONTROL  are the p roportions of patients alive and free of respiratory failure at Day 28  for 
reparixin and control groups, respectively.The null hypothesis H 0 will be rejected, and superiority of reparixin is 
declared if primary analysis  p-value will be lower than pre -specified threshold, depending at which analysis 
(interim or final) the test is performed. Thresholds are calculated according to O’Brien- Fleming spending function 
boundaries and are reported in Table 2 . 
 Primary endpoint will be analyzed by means of logistic regression adjusting by pre -defined baseline factors  (site, 
gender, age class, and presence of concomitant disease) and a one-sided test will be used to test for differences 
between treatment groups.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 55 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
Since patients who discontinue the IMP will not be withdrawn from the study but will be asked to complete safety and efficacy assessments as per the protocol, missing data will be address ed by modeling patients with missing 
data after retrieved drop -outs, assuming that missing data would have been like retrieved drop- outs if they were 
assessed . If there are no enough retrieved dropouts, a “wash- out” analysis instead of retrieved drop- out a nalysis 
will be performed: the missing primary endpoint at Day 28 will be imputed by wash -out the effect of treatment 
using placebo completers; this approach does not assume benefits for reparixin  in case of discontinuation and 
limits a post- discontinuatio n clinical effect to that of placebo.  
 
10.5.2.2 Sensitivity analyses 
The following sensitivity analyses are defined to assess the robustness of results on primary endpoint versus adherence to protocol and presence of missing data (details will be provided in the SAP):  
• The comparison between treatment and control will be performed in the PP population instead of FAS;  
• The comparison between treatment and control will be performed in the FAS population considering 
complete cases only (i.e. without considering patients with missing primary endpoints at Day 28) instead of MI under MNAR. This analysis will assess the robustness of results to the method of handling missing data.  
• The comparison between treatment and control will be performed in the FAS population by means of MI 
under missing at random (MAR) assumption instead of MNAR.  
• A tipping point strategy will be used as a sensitivity analysis for missing data for assessment of superiority (if shown) of reparixin . Tipping point, will ass ess how departures from MI under MNAR assumptions 
must be in order to overturn conclusions from the primary superiority analysis. Tipping point will be based on iterative application of MI.  
Additional sensitivity analyses may be added in the SAP.  
 
10.5.2.3 Secondary Analyses 
In case analysis of the primary endpoint leads to rejection of null hypothesis, the following key secondary endpoints will be tested in a conditional sequential manner to show superiority of reparixin versus control according to the following ranking:  
1. Proportion of patients alive and free of respiratory failure (as described for the primary endpoint ) at Day 
60,  
2.  Mortality rates up to Day 28 , 
3. Incidence of ICU admission up to Day 28, 
4. Time to recovery (category 1 - 2 - 3 of the 7- point WH O-OS of clinical improvement)  up to Day 28. 
This hierarchical test strategy protects the family -wise false positive error rate at the overall one -sided 0.025 level.  
Key secondary endpoints #1  , #2 and #3 will be analyzed by means of a logistic regression model ; key secondary 
endpoint  #4 will be analyzed as detailed in section  10.5.1. 
In case of futility at interim analysis or in case of not rejection of null hypothesis, the above test strategy will not be performed. Instead, independently of results on primary endpoint, descriptive in nature analyses will be 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 57 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
 
10.5.7 Missing data 
All reasonable efforts will be made to reduce the rate of missing data. Investigators will be trained about the importance of patient retention and full data capture. Also, any reasonable attempts should be made by the Investigators to emphasize continued subject’s participation for the full duration of the trial. However, in order to minimize missing data, if a patient cannot refer to the site for a planned follow -up visit, the Investigator will try to 
obtain any relevant information from the patients, including documents/laboratory results available from local medical care.  
   
  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 58 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
11 STUDY ORGANIZATION  
11.1 Study documentation and record keeping  
The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the source documents  and in all required reports.  
The investigator must keep source documents for each subject in the study.  
The investigator and the sponsor should maintain the study documents as specified in the “Essential Documents for the Conduct of a Clinical Trial” chapter 8 of ICH -GCP and as required by the applicable regulatory 
requirement(s).  
These are documents which individually and collectively permit evaluation of a study and the quality of the data  
produced and include groups of documents, generated before the study commences, during the clinical study, and after termination of the study and include but are not limited to, study protocol, amendments, submission and approval of E thics Committee (EC) , raw data of subjects, insurance contracts, certificate of analysis of the IMP(s), 
drug accountability records, signed informed consent forms, confidential subj ects identification code.  
The investigator and the sponsor should take measures to prevent accidental or premature destruction of these documents.  
Study documents must be retained by the investigator and the sponsor as long as  needed to comply with ICH -
GCP, national and international regulations. By signing the protocol, the investigator and the sponsor agree to adhere to these requirements.  
 
11.2 Ethical considerations, quality assurance and monitoring 
The procedures outlined  in this clinical trial protocol are designed to ensure that the Sponsor  and the  Investigators 
from the Clinical Sites perform their activities  throughout the set -up, conduct, evaluation , documentation and 
analysis of the study, in accordance to the principles of the Good Clinical Practice (GCP) guidelines of the 
International  Conference on Harmonization (ICH) and the Declaration of Helsinki. The study will be carried out 
adhering to local legal requirements  and the applicable national law s, whichever represents the greater protection 
for the individual s. 
Study protocol, patient information and informed consent will be submitted to the appropriate  Ethic s Committee  
(EC) / Institutional Review Board (IRB)  for approval. The Sponsor  will be responsible to  inform in a timely manner 
the appropriate Ethics  Committee  about any changes in the study protocol which could interfere with the patient’s 
safety.  
Due to the constrains and risks of the ongoing COVID -19 pandemia, no on- site monitoring activities will be carried 
out. Remote monitoring will be available periodically or at the investigators’ request via web or phone 
communications with the adequate Sponsor personnel or their approved representatives . 
 REGULATORY BODY APPROVAL  
Dompé or the CRO or other consultant appointed by Dompé will obtain the necessary approval from the Competent Authorities, as needed, prior to initiation of the study. The study will not be started until written approval from the 
relevant Competent Authorities (or no objection within the timeframe set by the local regulation, as applicable) 
has been received by Dompé.  
 
11.3 Informed consent  
The investigators or sub- investigators involved in this clinical trial who are responsible for  treating the hospitalized 
patient for COVID -19 are responsible for providing all necessary information  about the participation in the study 
to their  patients,  and consequently to obtain the written  Informed Consent.  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 59 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
The same procedure applies  to the information of the patient and providing of consent to the  processing of personal 
data according to the European Regulation n. 679/2016 on the Protection of Personal Data, the Personal Data 
Protection Code (Legislative Decree 196/03) and subsequent  amendments and additions, and to the provisions, 
guidelines and general authorizations of the  National Guarantor for p ersonal Data Protection. 
Information to the study participant is provided with a study- specific Information Sheet. The patient will eventually 
sign the Informed Consent Form for consenting to the study. A sample Informed Consent Form is reported in 
Apppendix 5.  
 
11.4 Data collection 
The investigator must ensure that the clinical data required by the study protocol are carefully reported in the 
subject’s source documents detailing the unique identification number and the date and time of the study procedures performed. Any correction to the source data entries must be carried out by the investigator or a 
designated member of staff. Incorrect entries must not be covered with correcting fluid, or obliterated, or made 
illegible in any way. A single stroke must be drawn through the original  entry. Corrections have to be dated and 
initialled. The investigator must provide a reasonable explanation for all missing data. The source documents will be completed, signed by the investigator, the sensitive data will be obscured (i.e. only randomizati on number will 
be clearly legible) and the source document will be made available to the Sponsor for data management procedures.  
Data Management will identify and implement the most effective data acquisition and management strategy for 
the clinical trial protocol and deliver datasets which support the protocol objectives.  Subject data will be entered 
into a defined CRFs and combined with data provided from other sources where applicable in a validated data 
system.  Subject initials will not be transmitted  for inclusion in the datasets.  Clinical data management will be 
performed in accordance with applicable standards and data cleaning procedures with the objective of removing 
errors and inconsistencies in the data which would otherwise impact on the analysis and reporting objectives, or the credibility of the Clinical Study Report. Adverse events and concomitant medications terms will be coded 
using validated dictionaries.  
   
11.5 Confidentiality and data protection  
By signing this protocol, the investigator agrees to keep all the information provided by the sponsor in strict confidentiality and to request the same confidentiality from his/her staff. Study documents provided by the sponsor 
(protocols, randomization list and other materials) will be stored  appropriately to ensure confidentiality. The 
information provided by the sponsor to the investigator cannot be disclosed to others without direct written 
authorisation from the sponsor, except for the extent necessary to obtain the informed consent from t he subjects 
wishing to participate in the study.  
  
Data on subjects collected in the source documents  during the study will be transferred to the Sponsor in an 
anonymized  way. If, as an exception, for safety or regulatory reasons identification of a subject becomes necessary, 
the sponsor and the investigator will be bound to keep this information confidential.  
   
11.6 Unique subject identifier  
All the subjects who sign th e informed consent form for the present study will be coded with “unique subject 
identifiers”. The unique subject identifier consists of the sponsor study code (i.e. REPAVID -19), the 3 -digit site 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 60 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
number (i.e. 001), the 4- digit screening number (e.g. S001, S002, etc.) and, if applicable, the 3- digit subject 
randomisation number (e.g. 001, 002, etc.).  
Study code, site number, screening number and subject randomisation number are separated by slashes (“/”).  
  
11.7 Database management  
This study will use an electronic CRF (eCRF) .  It will be  a web -based clinical trials data management system that  
provides investigational sites a standardised and validated, remote, electronic data capture system for the collection 
of clinical trial data.  Activities performed using the eCRF  include data entry, modification, review and validation.  
Each activity performed carries a unique user identification code and a date -time stamp.  
 An electronic audit trail of all changes made to the eCRF will be  kept within the eCRF . This audit trail identified 
the user making the change by userid, and date and time of change.  
 
Pre-defined data validation checks will be  run within the eCRF as the data were entered and submitted by 
authorised site staff .  The resu lting data queries will then resolved.   Additional queries will generated within the 
eCRF by authorized staff as a result of data review (e.g., source document review, external data reconciliation  etc).  
11.8 Coding dictionaries 
Medical/surgical history an d underlying diseases and AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA™). Previous and concomitant medications will be coded using the WHO Drug Dictionary Global, B3 format. The version of the coding dictionaries will be  stated in the study report.  
 
11.9 Publication policy  
Study results will be communicated in full to the competent Health Authorities by the submission of a complete clinical study report.  
The sponsor agrees that the study results may  be published by the investigator,  and the investigator agrees to 
submit any manuscript (abstract, publication, paper, etc.) to the sponsor before any public disclosure.  
This will be done in order to ensure that clinical study results are reported in an objective, accurate and balanced manner. The sponsor reviews the proposed manuscripts, before submission, within a reasonable period of time 
(30-90 days in relation with the complexity of the work).  
The investigator will also be provided by the sponsor with the clinical study report and the results of any additional 
analysis, tables, figures, etc. undertaken for the purposes of the article, in order to take responsibility for the content of the publication(s). On an exceptional basis, the sponsor may temporarily delay registration of certain data elements (e.g. compound, name, outcome, measures, etc.) to seek necessary intellectual property protection. This is because early disclosure of such data could, in some circumstances, prevent or negatively impact patentability.  
11.10 Administrative aspects  
The investigational medicinal products required for the conduct of this study will be provided free of charge by the Sponsor to t he participating clinical sites.  
Coverage for any damage resulting from the participation of the subjects in the clinical trial is  warrented. In 
addition to the general insurance of the individual participating clinical centers , an insurance cover will be issued 
in favour of the subjects participating in this clinical study. The insurance is in compliance with the local regulation 
and with the requirements of the Health Authorities.   
 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 61 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
12 REFERENCES  
 
1. Abraham E: Neutrophils and acute lung injury. Crit Care Med 2003;31:S195- 199 
2. Zhou X, Dai Q, Huang X: Neutrophils in acute lung injury. Front Biosci (Landmark Ed) 2012;17:2278 -2283  
3. Sheridan BC, McIntyre RC, Jr., Moore EE, Meldrum DR, Agrafojo J, Fullerton DA: Neutrophils mediate pulm onary vasomotor dysfunction in endotoxin- induced acute lung injury. J Trauma 1997;42:391- 396; discussion 
396-397 
4. Park I, Kim M, Choe K, Song E, Seo H, Hwang Y, Ahn J, Lee SH, Lee JH, Jo YH, Kim K, Koh GY, Kim P: Neutrophils disturb pulmonary microcircul ation in sepsis -induced acute lung injury. Eur Respir J 2019;53  
5. Nadeem A, Ahmad SF, Al -Harbi NO, Al -Harbi MM, Ibrahim KE, Kundu S, Attia SM, Alanazi WA, AlSharari 
SD: Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL -17A in neutrophils and gammadelta T cells respectively in mice. Int Immunopharmacol 
2019;68:39 -47 
6. Xie R, Yang Y, Zhu Y, Gao L, Jiang X, Sun J, Bian M, Yang J: Microparticles in red cell concentrates prime polymorphonuclear neutrophils and cause acute lung injury in a two- event mouse model. Int Immunopharmacol 
2018;55:98 -104 
7. Wang K, Lai C, Li T, Wang C, Wang W, Ni B, Bai C, Zhang S, Han L, Gu H, Zhao Z, Duan Y, Yang X, Xing L, Zhao L, Zhou S, Xia M, Jiang C, Wang X,  Yang P: Basic fibroblast growth factor protects against influenza A 
virus -induced acute lung injury by recruiting neutrophils. J Mol Cell Biol 2018;10:573- 585 
8. Wang F, Fu X, Wu X, Zhang J, Zhu J, Zou Y, Li J: Bone marrow derived M2 macrophages protected against 
lipopolysaccharide -induced acute lung injury through inhibiting oxidative stress and inflammation by modulating 
neutrophils and T lymphocytes responses. Int Immunopharmacol 2018;61:162- 168 
9. Saidi H, Berube J, Laraba -Djebari F, Hammoudi -Triki D: Involvement of Alveolar Macrophages and 
Neutrophils in Acute Lung Injury After Scorpion Envenomation: New Pharmacological Targets. Inflammation 2018;41:773- 783 
10. Rebetz J, Semple JW, Kapur R: The Pathogenic Involvement of Neutrophils in Acute Respiratory Distress 
Syndrome and Transfusion -Related Acute Lung Injury. Transfus Med Hemother 2018;45:290- 298 
11. Hirano Y, Ode Y, Ochani M, Wang P, Aziz M: Targeting junctional adhesion molecule -C ameliorates sepsis -
induced acute lung injury by decreasing CXCR4(+) aged neutrophils. J Leukoc Biol 2018;104:1159- 1171  
12. Blazquez -Prieto J, Lopez -Alonso I, Huidobro C, Albaiceta GM: The Emerging Role of Neutrophils in Repair 
after Acute Lung Injury. Am J Respir Cell Mol Biol 2018;59:289- 294 
13. Zhu Q, Wang H, Luo Y, Yu Y, Du Q, Fei A, Pan S: Protective effects of ethyl pyruvate on lipopolysaccharideinduced acute lung injury through inhibition of autophagy in neutrophils. Mol Med Rep 
2017;15:1272- 1278  
14. Sercundes MK, Ortolan LS, Debone D, Soeiro- Pereira PV, Gomes E, Ait ken EH, Condino- Neto A, Russo M, 
MR DIL, Alvarez JM, Portugal S, Marinho CRF, Epiphanio S: Correction: Targeting Neutrophils to Prevent 
Malaria- Associated Acute Lung Injury/Acute Respiratory Distress Syndrome in Mice. PLoS Pathog 
2017;13:e1006730  
15. Li L, Zhu C, Yuan Y, Li Z: Effect of rapamycin on early stage apoptosis of neutrophils in Sprague- Dawley 
rats with acute lung injury. Biomed Rep 2017;7:148 -152 
16. Wu D, Zeng Y, Fan Y, Wu J, Mulatibieke T, Ni J, Yu G, Wan R, Wang X, Hu G: Reverse -migrated neutr ophils 
regulated by JAM -C are involved in acute pancreatitis -associated lung injury. Sci Rep 2016;6:20545  
17. Sercundes MK, Ortolan LS, Debone D, Soeiro- Pereira PV, Gomes E, Aitken EH, Condino- Neto A, Russo M, 
MR DIL, Alvarez JM, Portugal S, Marinho CR, Ep iphanio S: Targeting Neutrophils to Prevent Malaria -Associated 
Acute Lung Injury/Acute Respiratory Distress Syndrome in Mice. PLoS Pathog 2016;12:e1006054  
18. Paris AJ, Liu Y, Mei J, Dai N, Guo L, Spruce LA, Hudock KM, Brenner JS, Zacharias WJ, Mei HD, Slamowitz AR, Bhamidipati K, Beers MF, Seeholzer SH, Morrisey EE, Worthen GS: Neutrophils promote alveolar epithelial 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 62 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
regeneration by enhancing type II pneumocyte proliferation in a model of acid- induced acute lung injury. Am J 
Physiol Lung Cell Mol Physiol 2016;311:L1062 -L1075  
19. Kelher MR, Banerjee A, Gamboni F, Anderson C, Silliman CC: Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two- event in vivo rat model. 
Transfusion 2016;56:3004- 3011  
20. Baudiss K, de Paula Vieira R, Cicko S, Ayata K, Hossfeld M, Ehrat N, Gomez-Munoz A, Eltzschig HK, Idzko 
M: C1P Attenuates Lipopolysaccharide- Induced Acute Lung Injury by Preventing NF -kappaB Activation in 
Neutrophils. J Immunol 2016;196:2319- 2326  
21. Hu R, Chen ZF, Yan J, Li QF, Huang Y, Xu H, Zhang XP, Jiang H: Endoplasmic Reticulum Stress of 
Neutrophils Is Required for Ischemia/Reperfusion- Induced Acute Lung Injury. J Immunol 2015;195:4802 -4809  
22. Xu XW, Yang XM, Jin ZX, Zhu SJ: [Effect of  Ginkgo biloba extract on the function of alveolar 
polymorphonuclear neutrophils in severe acute pancreatitis rats complicated with lung injury]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2014;34:460- 465 
23. Silliman CC, Bercovitz RS, Khan SY, Kelher MR, LaSarre M, Land KJ, Sowemimo -Coker S: Antibodies to 
the HLA -A2 antigen prime neutrophils and serve as the second event in an in vitro model of transfusion -related 
acute lung injury. Vox Sang 2014;107:76 -82 
24. Roychaudhuri R, Hergrueter AH, Polverino F, Laucho- Contreras ME, Gupta K, Borregaard N, Owen CA: 
ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. J Immunol 2014;193:2469- 2482  
25. Park DW,  Jiang S, Liu Y, Siegal GP, Inoki K, Abraham E, Zmijewski JW: GSK3beta -dependent inhibition of 
AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2014;307:L735- 745 
26. K rupa A, Fol M, Rahman M, Stokes KY, Florence JM, Leskov IL, Khoretonenko MV, Matthay MA, Liu KD, 
Calfee CS, Tvinnereim A, Rosenfield GR, Kurdowska AK: Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex- induced acute lung injury. Am J Physiol Lung Cell Mol 
Physiol 2014;307:L435- 448 
27. Van Ness M, Jensen H, Adamson GN, Kysar PE, Holland P: Neutrophils contain cholesterol crystals in transfusion- related acute lung injury (TRALI). Am J Clin Pathol 2013;140:170- 176 
28. Perl M, Hohmann C, Denk S, Kellermann P, Lu D, Braumuller S, Bachem MG, Thomas J, Knoferl MW, Ayala 
A, Gebhard F, Huber -Lang MS: Role of activated neutrophils in chest trauma -induced septic acute lung injury. 
Shock 2012;38:98- 106 
29. Chi X, Zhi L, Gelderman MP, Vostal JG: Host platelets and, in part, neutrophils mediate lung accumulation of 
transfused UVB -irradiated human platelets in a mouse model of acute lung injury. PLoS One 2012;7:e44829  
30. Su X, Looney MR, Su HE, Lee JW, Song Y, Matthay MA: Role of CFTR expressed by neutrophils in 
modulating acute lung inflammation and injury in mice. Inflamm Res 2011;60:619 -632 
31. Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew AA, Phoon MC, van Rooijen N, Chow VT: Excessive 
neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 2011;179:199- 210 
32. Grommes J, Soehnlein O: Contribution of neutrophils to acute lung injury. Mol Med 2011;17:293- 307 
33. Lee JP, Li YC, Chen HY, Lin RH, Huang SS, Chen HL,  Kuan PC, Liao MF, Chen CJ, Kuan YH: Protective 
effects of luteolin against lipopolysaccharide -induced acute lung injury involves inhibition of MEK/ERK and 
PI3K/Akt pathways in neutrophils. Acta Pharmacol Sin 2010;31:831 -838 
34. Zemans RL, Colgan SP, Downey GP: Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 2009;40:519- 535 
35. Hishizawa M, Mitsuhashi R, Ohno T: Transfusion- related acute lung injury (TRALI) induced by donor -derived 
anti-HLA antibodies in aplastic anemia: possible priming effect of granulocyte -colony stimulating factor (G -CSF) 
on the recipient neutrophils. Intern Med 2009;48:1979 -1983  
36. Fung YL, Silliman CC: The role of neutrophils in the pathogenesis of transfusion -related acute lung injury. 
Transfus Med Rev 2009;23:266- 283 

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 63 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
37. Awad AS, Rouse M, Huang L, Vergis AL, Reutershan J, Cathro HP, Linden J, Okusa MD: Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009;75:689- 698 
38. Inoue Y, Chen Y, Pauzenberger R, Hirsh MI, Junger WG: Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis. Crit Care Med 2008;36:2569- 2575  
39. Silva E, Arcar oli J, He Q, Svetkauskaite D, Coldren C, Nick JA, Poch K, Park JS, Banerjee A, Abraham E: 
HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis- induced acute lung injury. Intensive Care Med 2007;3 3:1829 -1839  
40. Zarbock A, Schmolke M, Spieker T, Jurk K, Van Aken H, Singbartl K: Acute uremia but not renal inflammation attenuates aseptic acute lung injury: a critical role for uremic neutrophils. J Am Soc Nephrol 
2006;17:3124- 3131  
41. Nishimura M, Takanashi M, Okazaki H, Satake M: Lung microvascular endothelial cell injury caused by 
treatment with polymorphonuclear neutrophils and low -IgM serum: a model of transfusion- related acute lung 
injury. Lung 2006;184:25- 32 
42. Looney MR, Su X, V an Ziffle JA, Lowell CA, Matthay MA: Neutrophils and their Fc gamma receptors are 
essential in a mouse model of transfusion- related acute lung injury. J Clin Invest 2006;116:1615 -1623  
43. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman 
CC: Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion- related acute lung injury. Blood 2006;108:2455- 2462  
44. Reutershan J, Basit A, Galkina EV, Ley K: Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS -induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005;289:L807- 815 
45. Zhang L, Shen KL, Zhou T, Xue YQ, Yang P: [Effects of hydrocortisone on oxygen free radicals released by 
polymorphonuclear neutrophils in lipopolysaccharide -induced acute lung injury in mice]. Zhonghua Er Ke Za Zhi 
2004;42:659- 662 
46. Wang S, Nie XH, Guo DY, Xiao H, Ren K: [Relative functional changes in neutrophils in early period of acute 
lung injury in rabbit]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004;16:403- 408 
47. Sevimli ZU, Dogan N, Kizilkaya M, Gundogdu C: Experimental acute lung injury. Effects of methylprednisolone and lidocaine on histopathology and neutrophils. Saudi Med J 2004;25:1831 -1834  
48. Nishimura M, Ishikawa Y, Satake M: Activation of polymorphonuclear neutrophils by immune complex: possible involvement in development of transfusion- related acute lung injury. Transfus Med 2004; 14:359- 367 
49. Li Q, Park PW, Wilson CL, Parks WC: Matrilysin shedding of syndecan- 1 regulates chemokine mobilization 
and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635 -646 
50. Azoulay E, Attalah H, Yang K, Jouault H, Schlemmer B, Brun -Buisson C, Brochard L, Harf A, Delclaux C: 
Exacerbation by granulocyte colony- stimulating factor of prior acute lung injury: implication of neutrophils. Crit 
Care Med 2002;30:2115- 2122  
51. Ueda M, Iwasaki Y, Harada H, Kubota Y, Yokomura I, Hashimoto S, Mizobuchi K, Nakagawa M: [Role of neutrophils in acute lung injury induced by Candida sepsis]. Nihon Kokyuki Gakkai Zasshi 2001;39:726- 731 
52. Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C, Sallenave JM: Adenoviral augmentati on of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial 
infection. J Immunol 2001;167:1778 -1786  
53. Grenier A, Combaux D, Chastre J, Gougerot -Pocidalo MA, Gibert C, Dehoux M, Chollet -Martin S: Oncostatin 
M production by blood and alveolar neutrophils during acute lung injury. Lab Invest 2001;81:133 -141 
54. Kinoshita M, Ono S, Mochizuki H: Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur Surg Res 2000;32:337 -346 
55. Abraham E, Carmody A, Shenkar R, Arcaroli J: Neutrophils as early immunologic effectors in hemorrhage - 
or endotoxemia -induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2000;279:L1137 -1145  
56. Hsu L, McDermott T, Brown L, Aguayo SM: Transgenic HbS mouse neutrophils in increased susceptibility to acute lung injury: implications for sickle acute chest syndrome. Chest 1999;116:92S  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 64 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
57. Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, Steer ML: The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis- associated lung injury. Gastroenterology 
1999;116:694- 701 
58. Mizgerd JP, Kubo H, Kutkoski GJ, Bhagwan SD, Scharffetter -Kochanek K, Beaudet AL, Doerschuk CM: 
Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18 -deficient mice. J Exp Med 1997;186:1357- 1364  
59. Winn RK, Mileski WJ, Kovach NL, Doerschuk CM, Rice CL, Harlan JM: Role of protein synthesis and CD11/CD18 adhesion complex in neutrophil emigration into the lung. Exp Lung Res 1993;19:221 -235 
60. Puneet P, Moochhala S, Bhatia M: Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005;288:L3 -15 
61. Keane MP, Donnelly SC, Belperio JA, Goodman RB, Dy M, Burdick MD, Fishbe in MC, Strieter RM: 
Imbalance in the expression of CXC chemokines correlates with bronchoalveolar lavage fluid angiogenic activity and procollagen levels in acute respiratory distress syndrome. J Immunol 2002;169:6515- 6521  
62. Miller EJ, Cohen AB, Matthay MA: Increased interleukin -8 concentrations in the pulmonary edema fluid of 
patients with acute respiratory distress syndrome from sepsis. Crit Care Med 1996;24:1448 -1454  
63. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, Weiner -Kronish JP , Sticherling M, 
Christophers E, Matthay MA: Elevated levels of NAP -1/interleukin -8 are present in the airspaces of patients with 
the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 1992;146:427- 432 
64. Fudala R, Krupa A, Stankowska D, Allen TC, Kurdowska AK: Anti -interleukin -8 autoantibody:interleukin -8 
immune complexes in acute lung injury/acute respiratory distress syndrome. Clin Sci (Lond) 2008;114:403- 412 
65. Allen TC, Fudala R, Nash SE, Kurdowska A: A nti-interleukin 8 autoantibody:interleukin 8 immune complexes 
visualized by laser confocal microscopy in injured lung. Arch Pathol Lab Med 2007;131:452- 456 
66. Kurdowska A, Noble JM, Grant IS, Robertson CR, Haslett C, Donnelly SC: Anti -interleukin -8 autoantibodies 
in patients at risk for acute respiratory distress syndrome. Crit Care Med 2002;30:2335- 2337  
67. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR: Anti -interleukin 8 autoantibody: 
interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med 2001;163:463 -468 
68. Krupa A, Kato H, Matthay MA, Kurdowska AK: Proinflammatory activity of anti -IL-8 autoantibody:IL -8 
complexes in alveolar  edema fluid from patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 
2004;286:L1105 -1113  
69. Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG: Fully human anti -interleukin -8 monoclonal antibodies: 
potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999;66:401 -410 
70. Zarbock A, Allegretti M, Ley K: Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury 
in mice. Br J Pharmacol 2008;155:357- 364 
71. Bhatia M, Hegde A: Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice 
against acute pancreatitis and associated lung injury. Regul Pept 2007;138:40- 48 
72. Lomas -Neira JL, Chung CS, Grutkoski PS, Miller EJ, Ayala A: CXCR2 inhibition suppresses hemorrhage-
induced priming for acute lung injury in mice. J Leukoc Biol 2004;76:58 -64 
73. Goncalves AS, Appelberg R: The involvement of the chemokine receptor CXCR2 in neutrophil recruitment in 
LPS- induced inflammation and in Mycobacterium avium infection. Scand J Immunol 2002;55:585 -591 
74. Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH: Nonpeptide CXCR2 antagonist 
prevents neutrophil accumulation in hyperoxia -exposed newborn rats. J Pharmacol Exp Ther 2001;299:90- 95 
75. Belperio JA, Keane MP, Burdick MD, Gomperts BN, Xue YY, Hong K, Mestas J, Zisman D, Ardehali A, 
Saggar R, Lynch JP, 3rd, Ross DJ, Strieter RM: CXCR2/CXCR2 ligand biology during lung transplant ischemia -
reperfusion injury. J Immunol 2005;175:6931 -6939  
76. Belperio JA, Keane MP, B urdick MD, Londhe V, Xue YY, Li K, Phillips RJ, Strieter RM: Critical role for 
CXCR2 and CXCR2 ligands during the pathogenesis of ventilator -induced lung injury. J Clin Invest 
2002;110:1703 -1716  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 65 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
77. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Sa prito MS, Ley K: Critical role of endothelial 
CXCR2 in LPS -induced neutrophil migration into the lung. J Clin Invest 2006;116:695- 702 
78. Stillie R, Farooq SM, Gordon JR, Stadnyk AW: The functional significance behind expressing two IL -8 
receptor types on PMN. J Leukoc Biol 2009;86:529- 543 
79. Hosoki K, Rajarathnam K, Sur S: Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor. Clin Exp Allergy 2019;49:130 -132 
80. I-Yin Cheng, Chen -Chi Liu, Jiun -Han Lin, Tien -Wei Hsu, Jyuan- Wei Hsu, Anna Fen -Yau Li, Wen -Chao Ho, 
Shih-Chieh Hung and Han- Shui Hsu Particulate Matter Increases the Severity ofBleomycin -Induced Pulmonary 
Fibrosis throughKC -Mediated Neutrophil Chemotaxis, Int. J. Mol. Sci.2020,21, 227  
81. Tavares LP, Ga rcia CC, Machado MG, Queiroz- Junior CM, Barthelemy A, Trottein F, Siqueira MM, 
Brandolini L, Allegretti M, Machado AM, de Sousa LP, Teixeira MM: CXCR1/2 Antagonism Is Protective during 
Influenza and Post -Influenza Pneumococcal Infection. Front Immunol 2017;8:1799  
82. Maffi P, Lundgren T, Tufveson G, Rafael E, Shaw JAM, Liew A, Saudek F, Witkowski P, Golab K, Bertuzzi 
F, Gustafsson B, Daffonchio L, Ruffini PA, Piemonti L: Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double -Blind, Randomized, Placebo- Controlled Trial in Type 
1 Diabetes. Diabetes Care 2020;  
83. Moriconi et.al ACS Med Chem Lett. 2011 Aug 7;2(10):768- 73.;  
84. Moriconi, Cesta MC, Cervellera MN, et al. Design of noncompetitive interleukin -8 inhibitors acting on CXCR1 
and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984- 4002.;  
85. Allegretti M , Cesta MC, Bizzarri C, et al. 2-Arylpropionic CXC chemokine receptor 1 ( CXCR1) ligands as 
novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312- 31.;  
86. Bertini R, Allegretti M, Bizzarri C., Moriconi A, Locati M, et al. A new class of non -competitive allosteric 
inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. PNAS 
2004; 101: 11791- 6  
 
    
 
    
 
     
 
   
  

    CONFORMED COPY TO THE ORIGINAL   
 
   Page 66 of 66 
     
REP0220_Final  Version No. 3.0_09/APR/2021  
EudraCT number 2020- 005919- 51 
 
13 APPENDICES  
 
Appendix 1. Investigator’s Brochure (IB) 
Please r efer to dedicated document 
 
 
 
Appendix 2. Investigational Drug Labels 
Please r efer to dedicated document 
  
 
Appendix 3. Severe Adverse Event (SAE) reporting form and completion guideline  
Please r efer to dedicated document 
  
 
Appendix 4. Pregnancy reporting form and completion guideline  
Please r efer to dedicated document 
 
  
Appendix 5. Informed consent form  
Please r efer to dedicated document 
 
 
  
 
